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ABSTRACT 
 
Kizzmekia Shanta Corbett: Characterization of Human Antibody Responses to Dengue Virus 
Infections in a Sri Lankan Pediatric Cohort 
(Under the direction of Aravinda de Silva) 
 
 Dengue virus (DENV) is the most significant mosquito-borne viral infection of humans.  
People infected with dengue viruses present with subclinical (inapparent) or clinically-apparent 
infections ranging from undifferentiated fever to dengue hemorrhagic fever or dengue shock 
syndrome. It is not completely understood why some people get more severely ill from DENV 
infections than others, but antibody responses have been implicated in playing a role facilitating 
severe dengue disease. To that end, we analyzed samples from a pediatric dengue cohort 
study in Sri Lanka to explore if antibody responses differentiated clinically inapparent and 
apparent infections. 799 children living in a heavily urbanized area of Colombo, Sri Lanka were 
followed for one year; samples were collected at enrollment, at follow-up, and intermittently from 
any child who acquired fever.  
Using those samples, we first obtained accurate estimates of the incidence of DENV 
infection and disease in the cohort. At enrollment, dengue sero-prevalence was 53.07% 
demonstrating high transmission in this population. Over the study year the incidence of DENV 
infection and disease were 8.39 (95% CI:  6.56-10.53) and 3.38 (95% CI: 2.24-4.88), 
respectively per 100 children per year. All together, we identified 35 primary (20 inapparent and 
15 apparent) and 32 secondary/repeat infections (20 inapparent and 12 apparent) over the 12-
month study period. The ratio of inapparent to apparent infections was 1.48:1. Secondly, we 
defined temporal regulation of the DENV-infected children’s antibody responses. Children who 
experienced primary infections had broad, serotype cross-neutralizing responses that narrowed 
in breadth to a single serotype over a 12-month period post infection. In children who 
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experienced repeat infections, IgG antibody levels fluctuated following infection, but 
neutralization breadth remained steady. Thirdly, we observed baseline antibody responses of 
children who got repeat infections. Children with pre-existing monotypic neutralizing responses 
were more likely to develop fever than children with cross-neutralizing responses. Pre-existing 
DENV neutralizing antibodies were correlated with protection from apparent dengue disease.  
Our results will be useful for obtaining more accurate estimates of the burden of dengue in the 
Indian subcontinent, and, most importantly, provide insight on protective antibody responses as 
they may be important for vaccine development.  
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CHAPTER ONE 
Background and Significance 
 
1.1 Dengue: the Virus 
Dengue virus (DENV), the causative agent of dengue disease, is an enveloped positive-
strand RNA Flavivirus, akin to other disease-causing viruses such as West Nile virus, Tick-
borne Encephalitis, and Yellow Fever virus. DENVs have been thought to exist as four distinct 
but antigenically related serotypes, DENV1-4, but data describing a new fifth DENV serotype, 
DENV5, has recently arisen [1]. Further complicating the dengue virus species, DENV 
serotypes can be additionally classified into regionally-specific genotypes.  
Infectious Life Cycle of Dengue Virus 
 DENV is transmitted to humans via the bite of infected Aedes aegypti and Aedes 
albopictus mosquitoes. Upon injection into the skin, DENV primarily targets mononuclear 
phagocytic cells, such as monocytes, macrophages, and dendritic cells [2]. To date, a specific 
human cellular receptor for DENV has not been identified. Several molecules have been 
identified to act as receptors or co-receptors on various mammalian cell types, including heparin 
sulfate [3, 4], CD14 [5], and heat shock proteins 70 (hsp70) and 90 (hsp90) [6]. Additionally, a 
few calcium-dependent (c-type) lectins are thought of as attachment factors for DENV; the most 
well-studied of these c-type lectins is dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin, DC-SIGN/CD209 [7-9]. Also, antibody-bound DENV can attach via 
cellular Fcγ-receptors during a process called antibody dependent enhancement (ADE), which 
is described in detail later in this chapter. 
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 The methods by which DENV is internalized after attachment to appropriate receptors 
and/or co-receptors (figure 1.1A) are still active areas of research (reviewed in [10]). Clathrin-
mediated endocytosis is largely accepted as the main method of internalization by DENV 
(figure 1.1B)  [11], although a clathrin-independent, dynamin-dependent internalization method 
used by DENV2 was identified in Vero cells as well [12]. Upon internalization, DENV particles 
are trafficked in early endosomes (figure 1.1C). Early endosomes mature into acidic late 
endosomes; low pH of late endosomes triggers DENV envelope (E) conformational changes 
[13, 14]. E homodimers dissociate, exposing the fusion loop (FL), which is then inserted into the 
cellular membrane.  E homotrimers form, and viral and host membranes bend toward each 
other and fuse together (figure 1.1D) [14, 15].  
As a result of viral to host membrane fusion, DENV nucleocapsid is ejected into the cell 
cytoplasm, where genomic viral RNA (vRNA) (figure 1.2A) is uncoated (figure 1.1E). DENV 
vRNA then travels to the rough endoplasmic reticulum (ER) where it is translated as a single 
polyprotein (figure 1.1F). Polyprotein processing occurs resulting in three structural proteins, 
capsid (C), pre-membrane (prM), and E, and seven nonstructural (NS) proteins, NS1, NS2A, 
NS2B, NS3, NS4A, NS4B, and NS5 (figure 1.2B).  Once the viral protease cleaved the 
precursor to generate active protein products, the proteins aggregate to form a replication 
complex. Subsequently, repeated cycles of vRNA synthesis and replication occur (reviewed in 
[16]). RNA is translated to make enough viral proteins to form new viruses, and vRNA is 
packaged by C to form nucleocapsids. Then, immature DENV virions, containing prM/E 
heterodimers, are assembled in the ER (figure 1.1G) and transported through the trans-Golgi 
network (TGN) (figure 1.1H). It is in the Golgi where furin cleaves prM thus resulting in mature 
DENV particles (figure 1.1I). Progeny DENV virions exit cells via host secretory processes 
(figure 1.1J). 
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Dengue Virion Structure 
 Mature dengue virions have icosahedral enveloped structures with a round core, 
containing multiple copies of C encapsidating the DENV RNA genome. The core is surrounded 
by a host-cell lipid bilayer containing 180 copies of membrane (M) and E [17]. The structure of E 
is biologically important in regards to neutralizing antibody epitopes; briefly, E consists of three 
domains, EDI-III, and a fusion loop at the tip of EDII (figure 1.3A). On a mature DENV virion, E 
is organized in 90 homodimers, which lay in sets of triples along the viral surface, creating a 
smooth appearance (figure 1.3C). Oppositely, immature dengue particles have a rough 
appearance because trimers of prM/E heterodimers form spikes on the surface of the particle 
(figure 1.3B,D) [18]. Dengue maturation state, as well as maturation of other flaviviruses, has 
been shown to be relevant to pathogenesis and antibody responses [19, 20].  Dengue virion 
structure will be related to antibody responses later in this chapter.  
1.2 Dengue: the Disease 
Global Epidemiology of Dengue  
Dengue virus infection is a widespread emerging global epidemic, with a projected two-
thirds of the world’s population at risk of exposure to DENV [21, 22]. Of all Ae. aegypti-borne 
viruses, including yellow fever virus and chikungunya,  DENV represents the greatest 
epidemiological and economic burden [23, 24]. In the last 30 years, DENV has spread into over 
100 countries, including the United States of America, leading to a four-fold increase of dengue 
disease [22]. Recent dengue outbreaks in Texas and Florida are true testaments to the 
continuous spread of DENV into previously unaffected areas and the emergence of dengue as a 
serious international disease threat [25, 26].  
There are several factors that are contributing to the global emergence of dengue virus 
infections [21]. For one, Ae. aegypti and Ae. albopictus, are populating new areas thus 
contributing to the unwavering spread of DENV globally [21-23, 27]. Notably also contributing to 
the spread of DENV is the increasing prominence of tropical urbanization worldwide [21].  Ten 
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years ago, estimates of the global dengue disease burden stated that 100 million total DENV 
infections occurred each year, 500,000 of which resulted in severe disease and over 20,000 that 
resulted in death [21, 22]. Since then, those estimates drastically increased as surveillance, 
detection, and records of dengue cases improved. In 2013, it was estimated that about 390 
million dengue infections occur around the world each year, which is a staggering 300% 
increase over previously published estimates [22, 28].  
Dengue in Sri Lanka 
 Risk of dengue virus infection is considered highest in tropical regions of Asia. Latest 
estimates from the global burden of dengue in 2010 state that Asia contributed to 67% of the 
world’s dengue infections, with 37% occurring in India alone [28]. Sri Lanka is an island country 
on the southern tip of the Indian subcontinent. Dengue virus has been present in Sri Lanka 
since at least 1966 [29, 30], though epidemiology of DENV infection in Sri Lanka has changed in 
recent years. There is documentation of a 10-fold increase in dengue fever (DF) and dengue 
hemorrhagic fever (DHF) cases in the last 10 years [30, 31]. Expansion of dengue across Sri 
Lanka coupled with introduction of new, possibly more virulent DENV genotypes have 
contributed to an increase in Sri Lankan dengue cases [30-33]. Crude estimations, based on 
surveillance cases reported to the WHO and cartographic estimates of global burden, state that 
there are about 2 million dengue cases that occur in Sri Lanka per year.  [28]. Until our studies 
were conducted, there was no data on the true burden of dengue virus infections in Sri Lanka, 
or even the entire Indian subcontinent. 
Clinical Presentation of Dengue Disease 
An estimated 1.4 million (70%) of the 2 million dengue infections that occur in Sri Lanka 
each year are inapparent infections. That percentage is about the same globally, with 75% of all 
dengue infections occurring sub-clinically [28].  Inapparent (asymptomatic) dengue infection, as 
characterized by the World Health Organization (WHO), occurs when an individual is infected 
with DENV but presents no clinical symptoms. Traditionally, apparent (symptomatic) infections 
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are thought to manifest clinically as dengue fever (DF), dengue hemorrhagic fever (DHF), or 
potentially-fatal dengue shock syndrome (DSS). DF consists of mild symptoms including, but 
not limited to, fever, joint pain, headache, and rash. DHF, the more severe form of dengue 
disease, includes symptoms of DF and is additionally characterized by plasma leakage. DSS, 
the most severe category of dengue disease, consists of signs of complete circulatory failure, 
manifesting as hypertension or irregular pulse [34]. In 2009, WHO modified its traditional 
classification system to broaden the complexity and applicability of apparent DENV case 
definitions. The newly revised system characterizes apparent dengue disease as dengue 
without warning signs, dengue with warning signs, and severe dengue, which are respectively 
similar to DF, DHF, and DSS, in regards to symptom descriptions [35]. Treatment of clinical 
dengue disease is simply a matter of close observation and symptom maintenance, mostly 
consisting of fluid replenishment [34]. (Refer to table 1.1 for a complete outline of WHO dengue 
case classification.)  
1.3 Role of Viral Factors in Dengue Disease Severity 
It is not fully understood why some individuals become more severely ill after dengue 
infections than others, although evidence shows viral factors play a role. Studies within the 
same cohort population have correlated specific DENV serotypes with severe disease 
outcomes. For example, a study in a Thai population showed DENV2 induced more severe 
disease than any of the other DENV serotypes [36, 37]. Introduction of new DENV clades into 
populations often have an effect on dengue disease severity, as well [32, 38-40]. DHF 
epidemics in Nicaragua have been associated with the introduction of new DENV2 clades [38]. 
A similar story exists with DENV3 clades in Sri Lanka [32, 39]. Recently even, a new DENV1 
genotype was associated with a severe dengue epidemic in Sri Lanka [33]. Subtle genetic 
differences between DENV strains have been shown to correlate with pathogenesis [31, 38, 41, 
42]. Additionally, DENV-encoded immune antagonists enable DENV to circumvent the host 
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immune system [43, 44].  NS5, for example, has the ability to inhibit type I interferon (IFN) 
signaling by binding to STAT2, which is a key component of the IFN pathway [43]. 
1.4  Role of Host Factors in Dengue Disease Severity 
Immune Responses to Dengue Virus Infection 
 Although DENVs encode human immune system antagonists, as a whole, immune 
responses are typically efficient enough to clear DENV infection. Dendritic cells (DCs) residing 
in the skin are thought to be the first line of defense against invading DENVs [45]. DCs become 
activated and produce tumor necrosis factor alpha (TNFα) and IFNα [46]. Generally speaking, 
IFN responses to DENV infection are robust as evidenced by upregulation of IFN-related genes 
in DENV-infected cells [47-51]. In several cell types, type I IFNs, IFNα [52] and IFNβ [53], play a 
role in controlling DENV early in infection. Additionally, natural killer (NK) cells have been shown 
to induce proinflammatory type II IFN production and lyse DENV-infected cells [54].    
  Innate immune activation initiates an adaptive immune response to dengue infection. 
Antigen processing and presentation is an integral part of adaptive immunity. DCs are essential 
in trafficking DENVs to the lymphatic system, from where the virus then spreads to other cell 
types. Macrophages (mθ) process and present DENV antigen to T and B lymphocytes (T cells 
and B cells) [55-57]. Antigens stimulate CD4+ T cells to produce IFNγ [58]. Strong CD8+ T cell 
responses are stimulated by DENV infection as well [59-61]. Upon seeing antigen, B cells 
clonally expand to produce DENV-specific antibodies [55, 56], which are discussed later in this 
chapter. 
Immunopathology of Dengue Virus Infection 
Immune responses are tailored to defend against invading pathogens, but in the case of 
DENV infection, immunopathology can play a key role in facilitating severe disease outcomes.  
Protection from or progression towards dengue disease is essentially a competition between 
protective versus pathogenic immune responses, respectively. As aforementioned, cytokines 
are instrumental components of the initial immune response to DENV infection, but 
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dysregulation of cytokine responses, namely “cytokine storm”, correlates with severe dengue 
disease. Comprehensively, analysis of cytokine profiles in dengue patients reveals many 
cytokines, including IFNγ, TNFα, and several interleukins (ILs), are associated with dengue 
disease severity (reviewed in [62]). One of the more recent of these studies showed that MIP1β, 
IP-10, and MCP-1, which are all associated with inflammatory responses, are higher in patients 
with dengue with warning signs compared to patients with dengue without warning signs [63].  
Cross-reactive CD8+ T cells are also correlated with DHF presence [59]. One 
mechanism of T cell immunopathology is decreased degranulation [64], and another is cytokine 
induction [64]. The standing theory is that cross-reactive T cells produce elevated levels of 
cytokines, and subsequently, cytokine signaling contributes to vascular leakage, which is a 
classic symptom associated with DHF and DSS [64]. Complement, which is typically thought of 
as a viral clearance mechanism, is insinuated in inducing vascular leakage as well.  While a 
helpful role for complement was shown in one study where DHF was associated with a 
reduction in complement components [65], other studies suggest an immunopathological role 
for complement. DENV NS1, an activator of complement signaling, and other key complement 
components are increased in fluids of DHF and DSS patients compared to DF patients [66, 67]. 
Also, in vitro, complement activation can enhance DENV uptake and viremia in myeloid cells 
[68].  
1.5 Human Antibody Response to Dengue Virus 
Role of Antibodies in Enhancement of Dengue Disease 
From the host’s perspective, the most significant risk factor for severe disease is 
previous exposure to DENV. Because DENVs circulate in waves of four serotypes, individuals 
are susceptible to multiple infections over a lifetime. A first infection is considered primary (1°) 
infection; repeat DENV infections are considered secondary (2°), tertiary (3°), and quaternary 
(4°). Secondary infections have long been correlated with more DHF and DSS than 1° infections 
[36, 69-73]. Studies with human monoclonal antibodies (huMAbs) show that a large proportion 
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of DENV antibodies induced after 1° infection are weakly neutralizing but cross-reactive [74-77]. 
Cross-reactive, sub-neutralizing DENV antibodies are thought to induce severe disease through 
a phenomenon known as antibody dependent enhancement (ADE) ([78] | reviewed in [79] and 
[80]) (figure 1.4).  
Serotype cross-reactive antibodies have been mapped to NS1, prM, and E [81-84]. 
These weakly neutralizing cross-reactive antibodies bind to DENVs (figure 1.4A), and antibody-
bound DENV particles then bind to Fc-gamma receptors, FcγRI and FcγRII, on appropriate 
moncocytic cells [85] (figure 1.4B).  ADE via FcγRII can be tricky because isoforms FcγRIIa 
and FcγRIIb, which are found on most DENV target cells, have stimulatory and inhibitory effects 
on DENV ADE, respectively [86, 87]. Entry via ADE is thought to occur in one of two fashions: 
(1) endocytosis, similar to the classical DENV entry pathway described above, or (2) 
phagocytosis, which occurs when aggregates of antibody-bound DENV particles sit atop a cell 
(figure 1.4C). In all, DENVs are engulfed by host cells thus increasing viral burden (extrinsic 
ADE) (figure 1.4E) and inducing cellular changes (figure 1.4D) that result in increased viral 
production (intrinsic ADE) (figure 1.4F).   
In vitro studies suggest extrinsic ADE can result in upwards of a 1000-fold increase in 
virus infection [88]. Increased DENV infection by ADE has been proven repeatedly in multiple 
cell systems, including human-isolated mθ, monocytes, and DCs, using huMAbs [89], mouse 
MAbs [90], and serum from DENV-infected individuals [91]. ADE may be a more effective 
method of infection due to the ability of immature DENV particles, which are noninfectious via 
classical receptor-mediated pathways, to be bound by prM-specific antibodies and taken up by 
FcγRs [19, 81].  DENV infection via ADE pathways dramatically changes innate immune 
responses. Most notably, ADE has been correlated with cytokine storm [92-94] and complement 
activation, both of which were discussed previously [65-67].  Effects of DENV ADE on IFN 
regulation are controversial, as some studies cite increases [95] and other studies cite 
decreases [96, 97] in IFN production following ADE. TLRs are instrumental in sensing 
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pathogens and inducing cytokine and IFN production. DENV ADE may affect IFN production by 
reducing toll-like receptor (TLR) expression and signaling. [94]. Overall, the likely effect of 
intrinsic ADE is increased viral replication and progeny virus output per infected cell.  
Role of Antibodies in Protection of Dengue Disease 
 Similar to other DENV immune responses, antibody responses can be either pathogenic 
(enhancing), as discussed in detail above, or protective (neutralizing). The DENV neutralizing 
antibody response consists of type-specific antibodies and cross-neutralizing antibodies. Dogma 
would have it that these antibodies facilitate protection from severe disease upon 2° infection 
with a homotypic or heterotypic DENV serotype, respectively. Early in the quest to dissect 
DENV antibody epitopes, mouse MAbs revealed a large portion of the DENV antibody response 
was directed to EDIII [98].  However, more recent mapping studies, using huMAbs and 
polyclonal human sera, show human antibody responses to DENV are different and more 
complex.  In fact, human antibodies recognizing EDIII are relatively sparse and furthermore play 
only a minute role in DENV neutralization [99].  
While strongly neutralizing mouse MAbs bind to recombinant E (rE) protein, strongly 
neutralizing huMAbs only recognize regions on intact DENV virions [77]. That finding was one of 
first to suggest a role for complex epitopes recognized by DENV neutralizing antibodies; since 
then more effort has been spent in understanding epitope specificity of DENV neutralizing 
antibodies. Strongly neutralizing huMAbs exerted antibody pressure on DENV in cell culture to 
render neutralization escape mutations around DENV EDI/II [77]. In studies of DENV1 vaccine 
recipients, it was found that amino acid mutations in EDI and EDII together were responsible for 
a type-specific antibody response [100, 101]. Structural analysis revealed a type-specific 
DENV1 neutralizing antibody epitope that spans the EDI/II hinge region of E monomers [102]. 
This region may be relevant to long-term type-specific DENV antibody response, as evidenced 
in an elegant EDI/II hinge transplant study [103].   
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Antibodies that confer potent neutralization across multiple DENV serotypes are less 
understood than type-specific antibodies. A few huMAbs that have potent broad neutralization 
capacity have been mapped to the FL region of E [104]. A potent broadly neutralizing huMAb 
that recognizes a region next to FL known as the “bc loop of EDII” was recently identified.  
However, FL-specific antibodies are typically weakly neutralizing, and, in fact, can confer 
enhancing activity [105]. The role for FL-specific antibodies in pathogenesis and/or protection is 
questionable, but a study using samples from a Nicaraguan cohort provides evidence that anti-
FL antibodies generated from 1° DENV infections correlate with protection against 2° 
heterologous infections [106]. 
Temporal Regulation of Dengue Antibodies 
One might imagine that the balance between pathogenic and protective DENV antibody 
responses is largely dependent on temporal regulation of antibodies following DENV infections. 
The field’s current understanding of antibody timing following DENV infections is summarized in 
figure 1.5 [36, 107, 108]. Upon 1° DENV infection, a person may begin to show symptoms 4-10 
days after inoculation. In the symptomatic or acute phase of illness, a person can exhibit viremia 
for up to 7 days; typical viremia lasts 5 days, peaking at day 3 of illness [36]. Length and 
magnitude of viremia is shortened during 2° infections [36, 107]. NS1 antigen circulates in the 
blood stream during the viremic period and is often used as a quick and easy method for acute 
diagnosis of DENV infection [109-111].  
IgG antibodies following 1° infection begin to appear after viremia wanes, at about day 
five post illness onset, and remain for a lifetime. Upon 2° infection, one is thought to experience 
a boost in IgG antibody levels that remains steady forever. IgM is more robust than IgG 
immediately following 1° infection and quickly wane to undetectable levels by 3-6 months [112]. 
IgM levels following 2° infection are not as robust and are even shorter lived than those 
following 1° infection [113, 114]. IgA and IgE antibodies have been detected following both 
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primary and secondary DENV infections, but temporal regulation and biological significance of 
these antibody subtypes remain unclear [114].  
More important than the timing of various types of antibodies is the timing of antibodies 
as they relate to pathogenic and protective disease outcomes. To that end, studies are being 
conducted to dissect temporal regulation of enhancing and protective antibody responses. 
Primary DENV infection with one serotype is dogmatically believed to lead to lifelong protective 
immunity to the infecting (homologous) serotype, but dengue-immune individuals remain 
susceptible to 2° infection with a different (heterologous) serotype [115]. It is thought that 2° 
infections induce antibody responses that are broadly-neutralizing and likely protective against 
post-secondary infections [116]. Even a 2° antibody response may not be completely protective 
because 3° and 4° infections, although rare, have been documented [70, 116-118].  
Some of the more telling research on how long protective antibody responses last was 
conducted in the 1950s; Sabin infected humans with DENV and challenged them with either a 
homologous or heterologous serotype. That study pronounced the period of type-specific 
protection to be at least 18 months while the period of cross-protection was only about 2 months 
[119]. Sabin’s last timepoint was 18 months, but studies have shown type-specific neutralization 
lasts up to 60 years post-infection [120]. Sequential infections in Thai and Nicaraguan cohorts 
reveal that 2° inapparent infections are more likely to occur within a shorter time span following 
1° infection than 2° apparent infections. Together, these studies determined the period of cross-
protection to be about 2 years [118, 121]. Perhaps, it is after 2 years that concentrations of 
weakly neutralizing cross-reactive antibodies decline and enhancement begins to occur [87].  
1.6 Advantages of Studying Dengue Virus Infections in Human Cohorts 
Mouse Models for Dengue Virus Pathogenesis 
 Studying vaccine-induced immunity and dengue pathogenesis in a small animal model 
has been difficult (reviewed in [122]). Mice infected with mouse-adapted DENV strains do not 
typically show classical signs of human disease. In the early stages of mouse model 
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development, neurological effects and paralysis, which are not clinical symptoms of human 
dengue disease, were seen in DENV-infected animals [123, 124]. BALBc and C57BL/6 mice 
have shown human-like DHF symptoms, but only after being inoculated with high doses of 
DENV [125]. In studies of DENV pathogenesis, humanized mice have a stark advantage over 
other mouse models because their cell tropism is similar to that of an infected human [126], and 
their disease presentation is similar to that of human DF [126, 127]. ADE has been shown 
multiple times in IFNI/II receptor-deficient AG129 mice [128, 129]. In the AG129 model, 
protection from ADE-induced disease is dependent on neutralizing antibodies [128]. In regards 
to antibody responses, it is important to restate that antibody responses in mice are drastically 
different than in humans [79, 99]. Furthermore, temporal regulation of DENV antibody 
responses and sequential DENV infections cannot be studied in mice due to their short life 
spans.  
Use of Non-human Primates in Vaccine-Related Studies 
Despite aforementioned pitfalls, mice are still a telling model for preliminary vaccine 
studies, especially because many mouse models exhibit disease symptoms that can be used as 
suitable protection endpoints [123, 124]. For advanced vaccine-related studies, it is imperative 
that disease manifestation and antibody responses resemble those seen in humans’. DENV 
pathogenesis is less well-studied in non-human primates (NHP) because they do not develop 
human-like clinical symptoms. However, early on DENV-infected Rhesus macaques were 
shown to have similar viremia and antibody responses as humans [130]. Before introduction into 
humans, DENV vaccines are often tested in NHPs [122, 131-136], and NHPs have proven 
rather useful in predicting vaccine-induced immunogenicity.  
Lessons Learned from Human Cohort Studies 
  With knowledge that antibody responses in mice [79, 99] and disease pathology in mice 
and NHPs alike are drastically different than humans’, it is ideal to study DENV pathogenesis in 
humans [137].  Over the years, several prospective dengue cohort studies have been 
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completed (Table 1.2). The lessons that cohort studies have taught the dengue field are 
immense (reviewed in [138]). Using samples collected from cohort studies, it has been shown 
that severe dengue disease correlates with several biological factors, such as age, and clinical 
outcomes, such as platelet count [139-143]. Results from cohort studies [144] were even 
influential in WHO’s reevaluation of clinically apparent dengue symptomologies [145-148].  
  Additionally, researchers are making progress with understanding DENV antibody 
responses in human cohorts. Cohorts in Thailand were the first to show previous DENV 
infection is a risk factor for severe disease [69, 70]. Later, several cohorts followed suit with 
similar findings [78, 128, 149-152]. Also, maternal antibodies have been correlated with severe 
dengue disease in Vietnamese infants [153, 154]. Together, these findings justify the theory of 
ADE in naturally infected people. As far as protective antibody responses are concerned, 
determining the natural correlate of protection from DENV infections and/or disease is a 
continuing challenge for the vaccine field. As previously mentioned, cohort studies provided us 
with the first evidence of clade-induced shifts in DENV immunity [32, 38-40]. In Thai cohorts, 
pre-existing neutralization titers did not correlate with protection from DENV infection with the 
same serotype, as evidenced by clinical symptoms and viremia [152, 155], but Thai cluster 
studies show that neutralization titer does correlate with protection from DENV infection 
[Buddhar, Darunee, et al. | unpublished data submitted to PLoS Neglected Tropical Diseases]. 
In a cohort in Peru, pre-existing neutralization breath correlated with protection from apparent 
post-secondary DENV infections [116]. Cross-protection following natural primary infections was 
determined to last about 2 years in Thai and Nicaraguan cohorts [118, 121].  
1.7 Dengue Vaccine Development 
In the wake of dengue emerging as a serious emerging global health problem, 
development of a DENV vaccine is urgently needed. However, dengue vaccine development 
has proven difficult. There are several criteria that a successful DENV vaccine must meet. 
Although young children are thought to be the target vaccine population, adults are still 
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susceptible to 3° and 4° DENV infections. Therefore, an ideal DENV vaccine should target a 
spectrum of age groups. Also, given the widespread circulation of DENV within poor nations, a 
DENV vaccine must be affordable. Most importantly, serotype-unbalanced vaccine responses 
run the risk of facilitating ADE upon natural challenge so an effective DENV vaccine must 
induce long-lived cross-protective responses against all DENV serotypes. Together these 
criteria present a vaccine development feat that, despite intense research efforts, has not been 
obtainable. To date, there is no DENV vaccine available to humans.  
Prospective Dengue Virus Vaccine Candidates 
Various approaches have been taken to develop a dengue vaccine. Subunit, subviral 
particles, or nonliving whole virus vaccines represent the safest class of DENV vaccines. There 
are a couple of nonliving DENV vaccines that stand out as potential vaccine candidates. The 
first is a tetravalent DNA vaccine that expresses DENV1-4  prM/E constructs [133], and the 
second is a tetravalent rE subunit vaccine  [132]. These types of vaccines typically induce 
subpar immunogenicity and require combination with adjuvants and viral vectors to provide an 
immune boost [156, 157]. Live-attenuated or recombinant DENV vaccines have been tested and 
generally show stronger, longer-lived neutralizing antibody responses than nonliving 
counterparts. Dengue virus can be attenuated via serial passage in cell culture so the virus no 
longer induces disease-causing infection but still induces an effective immune response. The 
efficacy of live attenuated DENV as a vaccine strategy was first tested by administering 
attenuated DENV2 to naïve individuals. In that small trial, DENV2-specific neutralizing antibody 
responses lasted for up to 2 years post-vaccination [158]. Live-attenuated DENV vaccines have 
evolved since then into tetravalent recombinant formulas administered at various prime/boost 
timepoints [131, 134, 159-177].  
There are three DENV live-attenuated vaccines (LAV) that stand out as promising 
human vaccine candidates. Steve Whitehead’s group has developed a tetravalent attenuated 
vaccine strategy, namely “TDV”, which consists of DENV prM/E from DENV1-3 inserted into an 
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attenuated DENV4 background. In human trial, vaccinees were challenged with DENV1 or 
DENV3 and were completely protected or partially protected, respectively [178]. DENVax is a 
LAV that has a DENV2 backbone with prM/E from the other serotypes inserted. In nonhuman 
primates, DENVax showed complete protection against DENV3 and DENV4 challenge, but only 
partial protection against DENV1 and DENV2 [135]. Recently completed human trials revealed 
DENVax induced broadly neutralizing antibody responses 30 days following inoculation [160]. 
Lastly is Sanofi Pasteur’s version of the DENV vaccine, CYD-TDV, which was thought to be the 
most promising candidate based on pre-phase IIB studies [179]. The chimeric tetravalent 
formulation consists of each of DENV1-4 prM/E inserted into the yellow fever vaccine backbone. 
Unfortunately, this vaccine showed only showed ~30-70% protection against natural DENV 
challenge in clinical trials, depending on serotype [180-187], and was notably deficient in 
protecting against DENV2 infection in a Thai trial [186].  
1.8 Outline of this Dissertation Research 
Research Questions 
  With levels of protection being lower than predicted with the leading DENV vaccine [180-
187], the field was reminded that there are fundamental aspects of protective responses that we 
do not understand.  Natural DENV infection protects most people against severe secondary 
infection so using protective immune responses to natural infection as a gold-standard may 
prove beneficial to the vaccine field. Three overarching questions exist about human antibody 
responses to DENV infection:  
(1) What are the differences between antibody responses induced by primary versus 
secondary infections? 
 (2) What role do enhancing antibodies play in disease severity? 
 (3) What role do neutralizing antibodies play in protection from dengue disease?  
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Research Approach 
  To that end, the overall goal of this dissertation was to characterize the role of antibodies 
in natural inapparent and apparent dengue infections. Based on knowledge that a balance of 
pathogenic and protective antibody responses can influence the severity of dengue disease, we 
hypothesize that distinct properties of pre-existing antibodies correlate with inapparent 
and apparent dengue disease outcome upon secondary infection.  In collaboration with the 
Pediatric Dengue Vaccine Initiative (PDVI) and investigators from the Ministry of Health in Sri 
Lanka, our group completed a prospective dengue study of 799 children, ages 0-12 years, who 
reside in Colombo, Sri Lanka. Using samples collected from the cohort, we addressed the 
following specific aims:  
Specific Aim 1 (Chapter Two). Determine the incidence of DENV infection in cohort. We  
set out to characterize the true burden of DENV infection, including inapparent cases, on 
the Indian subcontinent for the first time.  
Specific Aim 2 (Chapter Three). Investigate temporal regulation of antibodies following 
DENV infections.  
 2A. Compare quantity and neutralization capacity of antibodies acquired from 1° 
inapparent and apparent DENV infections.  
 2B. Determine how time post-infection influences antibody neutralization capacity 
following 1° infections.  
 2C. Characterize quantity and quality of antibodies following repeat DENV infections. 
Specific Aim 3. Investigate qualities of pre-existing antibodies from repeat inapparent 
and apparent DENV infections.  
 3A. (Chapter Four) Compare quantity, neutralization capacity, and enhancement ability 
of pre-infection antibodies from repeat inapparent and apparent DENV infections. 
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 3B. (Future Directions) Dissect infection history of children who acquired repeat DENV 
infection. 
Innovation 
  Our study is innovative because most previous studies have only detailed differences 
between mild DF cases and severe DHF/DSS cases because they are hospital-based studies 
that enroll patients upon acquisition of symptoms [69, 139, 140]. Given the complexity and cost 
of cohort studies, very few groups have pre- and post-infection blood samples from both 
inapparent and apparent cases. Even for studies that have been able to characterize inapparent 
infections, many have not specifically differentiated between 1° and repeat silent infections in 
their analyses [140, 141]. The findings that I detail in the following chapters will likely change the 
way the dengue field thinks about DENV antibody responses to natural infections in ways that 
will impact future dengue vaccine development.
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Table 1.1. World Health Organization Dengue Case Classifications 
 1997 World Health Organization Dengue Case Classifications [34] 
Case 
Classification 
Asymptomatic 
(Inapparent) 
Dengue Fever  
(DF) 
Dengue Hemorrhagic Fever 
(DHF) 
Dengue Shock Syndrome 
(DSS) 
Clinical 
Manifestations 
 no symptoms  fever 
AND ≥2 of the following… 
 retroorbital or ocular pain 
 headache 
 rash 
 myalgia 
 arthralgia 
 leukopenia 
 hemorrhagic 
manifestations not meeting 
DHF criteria  
ALL of the following… 
 fever (2-7 days) 
 hemorrhagic 
manifestations (positive 
tourniquet test or 
purpura/ecchymosis or 
epistaxis or gum bleeding 
or blood in vomit, urine or 
stool or vaginal bleeding) 
 thrombocytopenia 
 plasma leakage or pleural 
effusion or ascites or 
hypoproteinemia  
 rapid and weak pulse and 
narrow pulse pressure 
OR… 
 hypertension and cold, 
clammy skin and 
restlessness 
Other possible 
Symptoms 
  anorexia 
 nausea 
 abdominal pain 
 persistent vomiting 
  
2009 World Health Organization Dengue Case Classifications [35]  
 
Asymptomatic 
(Inapparent) 
Dengue 
without Warning Signs 
Dengue 
with Warning Signs Severe Dengue 
Clinical 
Manifestations 
 no symptoms 
 fever 
AND ≥2 of the following… 
 aches and pain 
 nausea, vomiting 
 rash 
 positive tourniquet test 
Dengue without warning signs 
AND ANY of the following… 
 abdominal pain 
 fluid accumulation 
 mucosal bleeding 
 restlessness 
 liver enlargement 
 decrease in platelet count 
Dengue with ≥1 of the following… 
 plasma leakage leading to 
DSS or fluid accumulation 
with respiratory distress 
 severe bleeding 
 severe organ involvement 
(liver | CNS – impaired 
consciousness | heart or 
organ failure)  
 
  
 
1
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Table 1.2. List of Prospective Dengue Cohort Studies1 
                                                          
1This table was taken from 138. Endy, Timothy P, Human Immune Responses to Dengue Virus Infection: lessons learned from 
prospective cohort studies. Front Immunol, 2014. 5. 
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Figure 1.1. Dengue virus infectious life cycle. (A) DENV attaches to cells via appropriate 
receptors and/or co-receptors, and is (B) internalized via clathrin-mediated endocytosis. (C) 
DENV travels in an early endosome, which matures into a late endosome. (D) pH changes in 
the late endosome induce DENV envelope conformational changes and the viral and host-cell 
membranes fuse. (E) DENV nucleocapsid exits into cell cytoplasm, and vRNA is uncoated. (F) 
vRNA travels to the rough ER where polyprotein processing and RNA synthesis and replication 
occur. RNA is encapsulated, and (G) an immature DENV particle, with prM/E heterodimers 
assembles in the ER. (H) Immature DENVs travel to the TGN and undergo (I) viral maturation; 
prM is cleaved by furin. (J) Lastly, mature virions are released from the host cell. (This figure 
was adapted from [188].) 
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Figure 1.2. Dengue virus genome and polyprotein. (A) DENV RNA genome is (B) translated 
and processed as a polyprotein at the ER. ((A) was adapted from [189]. (B) was adapted from 
[190].) 
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Figure 1.3. DENV virion structure. (A) DENV E consists of three domains, EDI (red), EDII 
(yellow), EDIII (blue) and a fusion peptide. (B) prM/E heterodimers are organized on the surface 
of an immature DENV particle, creating a jagged appearance. (C) Ninety homodimers of E are 
organized flatly on the surface of a mature DENV particle, creating a smooth appearance. (D) 
Immature DENV particles are assembled in the ER and matured in the TGN. Mature DENV 
particles, and pr peptides, are excreted from the host cell. ((A) and (C) were adapted from [14]. 
(B) and (D) were adapted from [79].) 
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Figure 1.4. Antibody dependent enhancement of dengue virus. Upon secondary dengue 
infection, (A) heterotypic weakly-neutralizing antibodies from previous infection bind to DENV 
particles. (B) Antibody-bound DENVs are attached to monocytic cells via Fcγ receptors. (C) 
DENVs are endocytosed or phagocytized. (D) Various internal cellular processes are 
dysregulated. This entire process results in (E) increased virus infection (extrinsic ADE) and (F) 
increased viral load (intrinsic ADE).  (This figure was adapted from [191].) 
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Figure 1.5. Temporal regulation of antibodies following DENV infection. (This figure was 
adapted from [192].) A person can exhibit viremia for up to 7 days [36], although length and 
magnitude of viremia is shortened during 2° infections [36, 107]. NS1 antigen circulates in the 
blood stream during the viremic period [109-111]. IgG antibodies (yellow line) following 1° 
infection begin to appear at about day five post illness onset and remain for a lifetime. Upon 2° 
infection, one is thought to experience a boost in IgG antibody levels that remains steady 
forever. IgM (red line) is more robust than IgG immediately following 1° infection and quickly 
wane to undetectable levels by 3-6 months [112]. IgM levels following 2° infection are not as 
robust and are even shorter lived than those following 1° infection [113, 114].  
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CHAPTER TWO 
Burden of Dengue Infection and Disease in a Pediatric Cohort in Urban Sri Lanka 
2 3 4 
 
2.1 Introduction 
Dengue is caused by four related mosquito-borne dengue viruses (DENV1-4), which are 
endemic in many tropical and subtropical regions of the world. Most individuals infected with 
DENV are asymptomatic or develop a febrile illness known as dengue fever (DF), but in a 
minority, disease can be more severe and progress to dengue hemorrhagic fever and dengue 
shock syndrome (DHF/DSS). Infection with one DENV serotype confers protective immunity to 
future infections with that serotype only and these individuals are susceptible to secondary 
infections with heterologous serotypes [79]. Individuals suffering from secondary DENV 
infections are at a greater risk of developing DHF/DSS compared to individuals experiencing 
their first infection [189, 193]. 
Globally, an estimated 2.5 billion people are at risk for DENV infection, with estimated 
390 million annual DENV infections and 96 million dengue cases [28]. From prospective 
community and school based cohort studies, it has been possible to obtain estimates for the 
                                                          
2
This chapter was previously published. | Tissera H, Amarasinghe A, de Silva A.D., Palihawadana P, 
Kariyawasam P, Gunasena S, Corbett K.S., Katzelnick L, Tam C, Letson G.W., Margolis H.S.,  and 
de Silva A.M., Burden of dengue infection in a pediatric cohort in urban Sri Lanka. American Journal of 
Tropical Medicine and Hygiene, 2014. 91(1): p. 132-7. 
3
Portions of this chapter are in press. | Corbett K.S., Katzelnick L, Tissera H, Amarasinghe A, de Silva 
A.D., and de Silva A.M., Pre-existing Neutralizing Antibody Responses Distinguish Clinically Inapparent 
and Apparent Dengue Virus Infections in a Sri Lankan Pediatric Cohort. Journal of Infectious Diseases. 
 
4
This study was funded by the Pediatric Dengue Vaccine Initiative (Bill and Melinda Gates Foundation 
Grant #: 23197). Additional funding was provided by UNC Virology Training Grant (NIH Grant #: 
T32AI007419) and Initiative for Minority Student Development (NIH Grant #: 5R25GM055336). 
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incidence of DENV infection and disease for sites in southeast Asia [141, 194-198] and Latin 
America [199-201]. Although dengue is emerging in the Indian subcontinent and is considered a 
major health issue, we do not have estimates of the true burden of DENV infection and disease 
in this region.   
Dengue was first reported in Sri Lanka in the 1960s [29]. Studies conducted from 1980-
1984 showed a DENV seroprevalence of 50% among school children, with an annual 
seroconversion rate of 10-15% among 5−7-year-old school children in Colombo, the capital of 
Sri Lanka [39, 202]. More recently, analysis of age-stratified seroprevalence data indicated that 
the annual seroconversion rate among children <12 years in Colombo is around 14% [202]. In 
the past, most dengue cases have been reported from the Colombo district and other 
neighboring districts in the heavily urbanized southwestern region of the country. However, over 
the past 10-15 years dengue has been reported from nearly all districts of the island, and over 
the past two decades, the number of reported DF and DHF cases has increased by over 10-fold 
[31].  This increase in cases has been attributed to introduction of new genotypes of DENV as 
well the expansion of the range of the virus on the island [31-33]. In many ways, the changing 
epidemiology of dengue in Sri Lanka mirrors events in other parts of the subcontinent including 
India, which has also documented large increases in cases and appearance of new virus strains 
[203, 204]. We conducted a population-based study to determine the incidence of symptomatic 
and asymptomatic DENV infection among children living in Colombo, Sri Lanka, an urban 
setting of the Indian subcontinent. 
2.2 Materials and Methods 
Ethical Approval for Study 
Ethical approval for this research was obtained from the Ethical Review Committee of 
the Faculty of Medicine, University of Colombo, Sri Lanka and the Institutional Research Board 
of the International Vaccine Institute, Seoul, Korea. Only the children whose parents or legal 
guardians provided written informed consent were enrolled in the study. 
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Study Site  
The study was conducted in the city of Colombo, the commercial capital of Sri Lanka, 
which has a population of 647,100 and is the most densely populated area in the country with 
17,353 persons per square kilometer [205]. The city is divided into 47 municipal wards and ward 
33 was selected for the study because of its stable population, which reflects the socio-
economic status and demographics of the entire municipal area. The ward is endemic for 
dengue with the catchment population seeking healthcare in the tertiary care institution situated 
within its boundaries (Figure 2.1). 
Study Population  
A prospective cohort study was conducted between November 2008 and January 2010. 
The protocol for the study is described in detail elsewhere [206]. In brief, a house-to-house 
census was conducted by research assistants to determine the size, socio-demographic 
information and health-seeking patterns of the permanent resident childhood population <12 
years of age.  A representative sample of 800 children <12 years of age was recruited for the 
current study. The sample size calculation was based on the ability to detect an annual 
incidence of dengue of 10% with an absolute precision of 3%. The estimated sample size was 
then inflated by 30% to allow for possible loss to follow-up during the study period. All children 
were enrolled in the study following written informed consent from parent/legal guardian and 
assent from children > 7 years of age.  Each participating household was given a thermometer 
and each child was given an identification card with a unique study number. A febrile illness was 
defined as a temperature of ≥38°C lasting ≤7 days in any child in the study cohort documented 
by the parent, research assistant or health care professional. Following assessment and 
treatment by a designated physician, the research assistants interviewed the patient and parent 
using a standard case investigation form.  
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Sample Collection  
Blood samples were collected from all children at enrollment (Between November 2008- 
January 2009) and one year after enrollment (between November 2009 and January 2010) by 
finger prick and stored as blood spots on protein saver card (Whatman & ID Biological systems, 
USA) [207, 208].  From children with a documented fever, whole blood was collected by 
venipuncture into EDTA containing tubes.  Some of the whole blood was used to prepare dried 
blood spots for later serological testing.  The remaining blood was centrifuged and the plasma 
used for molecular diagnostic testing.  Ten or more days after recovery from fever, convalescent 
samples were collected by finger prick and stored as blood spots on protein saver cards.   
DENV Strains Used for Laboratory Assays 
The WHO DENV reference strains, i.e. DENV1 West Pac 74, DENV2 S-16803, DENV3 
CH54389 and DENV4 TVP-360 were used for preparing antigen and infectious stocks for 
serological assays. The WHO reference viruses were initially obtained from Dr. Robert Putnak 
(Walter Reed Army Institute of Research, Silver Spring, MD). Infectious stocks of virus were 
prepared using the C6/36 mosquito cell line and dengue antigens were harvested from Vero 
cells as previously described [209].  
Molecular Detection of DENV  
Plasma obtained during the acute phase of the febrile illness was tested by reverse 
transcriptase polymerase chain reaction (RT-PCR) to detect and serotype DENVs as previously 
described [31]. 
Detection of anti-DENV IgM and IgG Antibodies in Dried Blood Spots 
Antibodies were eluted from dried blood spots by submerging the filter paper in PBS and 
incubating for 37C for 2.5 hrs.  The final volume of the eluted antibody was adjusted to obtain a 
1:50 or 1:100 dilution of the original blood volume applied to the filter paper.  A recent report 
validated the use of dried blood spots for dengue serology [210]. 
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We performed dengue IgM capture ELISA as described [211],  except we used anti-
flavivirus monoclonal antibody 4G2 followed by enzyme-conjugated goat anti-mouse IgG to 
detect captured DENV antigen. In brief, 96-well plates were coated (overnight, 4°C) with 100 
μL/well (1 ng/μL) of goat anti-human IgM (Sigma, St. Louis, MO, USA) at a concentration of 0.1 
mol/L in carbonate buffer (pH 9.6). Plates were washed 3× in Tris-buffered saline with 0.2% 
Tween 20 (TBST) and blocked with 200 μL/well of 1× Tris-buffered saline with 0.05% Tween 20 
and 3% nonfat dry milk. Paired serum samples were tested on the same plate. Diluted serum 
(1:50) was loaded in duplicate and incubated (37°C, 1 h) to capture IgM antibody. Unbound 
antibody was washed, and wells were successively incubated with DENV antigen (mix of 
serotypes DEN1–4), mouse anti-flavivirus 4G2 mAb, and human-absorbed alkaline 
phosphatase (AP)–conjugated goat anti-mouse IgG antibody (Sigma). Optical density (OD) was 
measured at 405 nm after final incubation with AP substrate. 
Dengue IgG ELISA was performed as described [212]. Plates were coated overnight 
(4°C) with 100 μL/well of mouse anti-flavivirus 4G2 mAb at a concentration of 0.1 mol/L in 
carbonate buffer (pH 9.6) and then washed 3× in TBST. Plates were then blocked with standard 
diluents and successively incubated (37°C, 1 h) with DEN1–4 antigen, diluted serum (1:100) in 
duplicate wells, and AP-conjugated goat anti-human IgG (Fc portion), with 3 washings (TBST) 
between incubations. Plates were read at 405 nm after a final incubation with AP substrate (15 
min, room temperature, in the dark). 
Measurement of DENV Neutralizing Antibodies 
The presence of DENV neutralizing antibody was determined using a flow cytometry-
based neutralization assay with U937 monocytic cells stably transfected with dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) as previously 
described [213]. This flow cytometry based neutralization test has comparable specificity to the 
conventional dengue plaque reduction neutralization test and does not detect antibodies against 
Japanese encephalitis virus (Broadwater and de Silva unpublished data) [213].  Blood samples 
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were serially diluted (4 fold dilutions starting at 1:40 and ending at 1:10,240) and the serum 
dilution that neutralized 50% of the viruses was calculated by nonlinear, dose-response 
regression analysis with Prism 4.0 software (GraphPad Software, Inc., San Diego, CA). 
Determining Dengue Serostatus at Study Enrollment  
Dengue virus serostatus (DENV naïve or immune) at enrollment was determined by 
dengue IgG immunoassay. An OD value > 0.3 were considered dengue antibody positive.  
During the study period, primary infections were defined as dengue naïve children at enrollment 
who experienced an infection.  Secondary infections were defined as dengue immune children 
at enrollment who experienced an infection. 
Criteria for Laboratory Diagnosis of DENV infections  
A laboratory-confirmed clinically apparent dengue case was a child with a febrile illness 
who tested positive in at least two out of the three diagnostic assays (PCR, rising levels of IgM 
and/or IgG antibodies in paired acute and convalescent blood samples).  In the few cases 
where there was only an acute blood sample, the diagnosis was based on RT-PCR testing only. 
Apparent dengue cases were further classified as primary or secondary based on baseline 
DENV naïve or immune status, respectively.  
Inapparent infections were classified as new DENV infections occurring in children who 
did not have a laboratory-confirmed apparent dengue fever during the study year. To detect 
primary inapparent infections, paired baseline and end-of-year blood samples from all children 
were tested by IgG immunoassay. Dengue-naïve children at enrollment (391 children) who 
seroconverted over the study year (baseline sample seronegative and end-of-year sample 
seropositive [> 0.3 OD units]) were classified as primary infections.  DENV-immune children at 
enrollment (441 children) who displayed rising levels of anti-DENV IgG antibodies by the end of 
the year (> 0.1 OD units) were initially classified as secondary infections.  However, gold-
standard neutralization testing of these secondary infections (as classified by IgG increases) 
indicated no neutralization capacity increase over the study year.  
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Therefore, all children were screened for increased neutralization capacity over the 
study year by subjecting paired baseline and 12-month follow up samples from all children (at 
dilutions of 1:40 and 1:640) to a FACS-based neutralization assay against each of the four 
dengue serotypes (Table 2.1). Those children showing an increase in neutralization capacity by 
2-dilution screen were then confirmed by neutralization assay [213, 214] with full serum dilution 
series (Figure 2.2). To establish criteria for defining secondary infections using paired samples 
collected 12 months apart, we used a test set of 8 symptomatic secondary cases (detected by 
PCR and serology performed on samples collected within 1 month of acute infection). Only half 
the cases (4/8) cases displayed a 4-fold or greater increase whereas all cases (8/8) displayed a 
2-fold or greater increase in neutralizing antibody levels when paired baseline and end-of-year 
samples from these children were tested.  Therefore, children who had >2 fold increases in 
levels of neutralizing antibodies to one or more serotypes by the end of the year were 
designated as secondary infections.  Samples were tested at least twice and only paired 
samples that displayed a reproducible 2 fold-increase were included as new secondary 
infections. Although it is possible that some inapparent infections were actually dengue fever 
cases that were missed, efforts were made to ascertain case detection by educating parents 
and having a study team visit each house weekly [215]. Loss to follow-up was minimal; of 800 
children enrolled, only 1 child dropped out during the 12 months [215, 216].    
2.3 Results 
Notably, all DENV cases (inapparent and apparent) in this study were confirmed by 
neutralization assay [213, 214] with full serum dilution series (Figure 2.2). While the DENV 
neutralization assay is the gold standard assay for detecting new infections by serology, DENV-
specific IgG ELISAs are faster and easier to perform than neutralization assays. Paired samples 
were tested by both IgG ELISA and neutralization test to assess the performance of the IgG 
assay for detecting new infections using samples collected 12 months apart (Table 2.2).  While 
the IgG assay performed well for detecting primary infections (sensitivity of 94.3% and positive 
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predictive value (PPV) of 76.7%), the assay performed poorly for secondary infections 
(sensitivity of 62.5% and a PPV of only 29.9%) These results indicate that IgG ELISA is an 
unreliable method for identifying true DENV infections, particularly 2° infections, when utilizing 
paired samples collected 12 months apart.  
Between November 2008 and February 2009 a total of 800 children ages 0-12 years 
were enrolled in the study from ward 33 (Figure 2.1), these being representative of the age and 
demographic distribution of the 2527 children known to be permanent resident of the ward.  
Only 1 child was lost to follow up during the study period.  The dengue seroprevalence at 
enrollment was determined by testing all children by ELISA for the presence of DENV binding 
IgG antibodies (Table 2.3).  To confirm that IgG seropositivity was due to dengue infection and 
not exposure to related Japanese encephalitis virus (JEV), which is also present in Sri Lanka, all 
IgG positive samples were tested for the presence of DENV neutralizing antibodies.  The vast 
majority (96%) of IgG positive sera also neutralized DENV indicating that in this population the 
results of the IgG ELISA reflected dengue seroprevalence. The overall dengue seroprevalence 
was 53% at enrollment (Table 2.3). The age specific seroprevalence steadily increased with 
advancing age from a low of 22% in the youngest (<1 year) age group to a high of 74.26 % in 
the oldest (10-12 year) age group (Table 2.3).  
A total of 681 fever episodes were detected among the 799 children indicating that on 
average each child reported 0.9 fever episodes over one person-year of follow-up (Table 2.4).  
Dengue was laboratory-confirmed in 3.9% (27/681) of the fever episodes (Table 2.4); no child 
had more than one episode of dengue fever over the course of the study.  Therefore, the 
incidence of clinically apparent dengue in the cohort was 3.38 per 100 children per year (Table 
2.4).  When combined with the clinically inapparent infections, the total incidence of DENV 
infection was 8.39 per 100 children (Table 2.4). The highest incidence of infection and disease 
was in the 1-3 year group.  The overall ratio of inapparent to apparent infections was 1.48.  
 33 
 
Out of the 65 new apparent and inapparent DENV infections, 34 were primary infections 
and 31 were secondary infections (Table 2.5).  As might be expected, the ratio of primary to 
secondary infections decreased with age from 3 in the youngest (< 1 year) age group to 0.75 in 
the oldest (10-12) age group (data not shown).  The ratios of inapparent to apparent infections 
were not statistically significantly different (P>0.1) between primary and secondary infections 
(Table 2.5). 
The prevalence of each DENV serotype during the study year was estimated by 
identifying the serotypes responsible for primary infections (Table 2.6). DENV2 was the most 
common serotype (49%) followed by DENV3 (27%), DENV1 (23%) and DENV4 (3%). The 
number of people with monospecific neutralizing Abs to each serotype at enrollment into the 
study was used to estimate the prevalence of each serotype in this population before the start of 
our study (Table S1).  This analysis demonstrated that DENV2 (43%) and DENV3 (29%) were 
more common than DENV1 (9%) and DENV4 (12%) in the period preceding the study. 
2.4 Discussion 
Over the past two decades dengue has emerged as a major health problem in the Indian 
subcontinent [203, 204].  Dengue epidemics in the region have been linked to more intense 
transmission, expansion of the range of the virus and introduction of new strains [31-33, 203, 
204].  Most estimates of dengue incidence in the region are based on hospital-based studies 
and nationally reported cases, which grossly underestimate the true burden of disease and 
infection [217]. In this study, we followed a cohort of 799 children in Colombo, Sri Lanka to 
gauge the true burden of infection in this region.  
A strength of our study is that infections were detected by testing paired baseline and 
follow-up blood samples by neutralization test. This approach is not feasible with most cohort 
studies given the difficulty of testing large sample panels using the DENV neutralization test.  
We overcame this hurdle by using a 96-well format, flow cytometry based, high throughout 
neutralization assay [213, 214]. We screened baseline and follow-up samples from all enrolled 
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children at 2 dilutions for the presence of neutralizing antibody before selecting samples for 
more comprehensive neutralization testing.  Our study demonstrates that while simple to 
perform, IgG ELISA and related assays are unreliable methods for detection of DENV infections 
when samples are collected 12 months apart, particularly for repeat infections.  
Having fully characterized primary and secondary DENV infections in the cohort using 
neutralization assay, we estimated the incidence of infection and disease to be 8.39 and 3.38 
per 100 children respectively.  The ratio of clinically inapparent to apparent infections was 1.48 
indicating that for every apparent infection there were approximately 1.5 inapparent infections in 
children.  This high intensity of transmission was also supported by the seroprevalence data that 
demonstrated a gradually rising prevalence with age that ranged from 22% in the youngest age 
group to 74% in the oldest age group.  The 4 DENV serotypes were circulating in this population 
both before and during our study, with serotypes 2 and 3 being more prevalent than 1 and 4 
(Table 2.6). Our study establishes a rigorously measured, accurate burden of dengue infection 
and disease among children living in an urban area of Sri Lanka.  
Recently, we used dengue seroprevalence data from this cohort to model the rate of 
primary infections in dengue naïve children [202]. Using a catalytic model, we estimated the 
incidence of primary infection to be 14.1% per year (95% CI: 12.7%– 15.6%), which is higher 
than the incidence 8.39 % (95% CI: 6.56-10.53) observed here for total infections (primary and 
secondary infections).  A more legitimate comparison would be to compare the model based 
estimate for primary infections with the incidence of primary infections in our cohort.  The 
incidence of primary infection noted in the current study was 9.8% (95% CI: 6.80-12.80), which 
is closer to the model-based estimate of 14.1% per year (95% CI: 12.7%– 15.6%). A previous 
study of school children in Colombo over a 5-year period from 1980-1985 estimated the 
incidence of new infections to range between 10.78 to 18.54 per 100 children in different years 
[39]. Collectively, these findings demonstrate intense transmission of dengue among children in 
Colombo.   
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Our current estimate for disease (3.38 per 100 under 12 years of age population) is 14- 
fold higher than the reported national incidence of the disease (0.23 per 100 individuals) among 
<15 years of age in 2010 in Sri Lanka, which is based on the passive national surveillance 
system (Epidemiology Unit, MoH).  Based on national surveillance for 2010, the disease 
estimates for children less than 15 years in the Colombo district and the Colombo Municipality 
(study area) (See Figure 2.1) were 0.64 and 1.61 per 100 population respectively.  Thus, as 
expected the passive national program underreports the true burden of disease in Sri Lanka. 
Recent studies in SE Asia have estimated expansion factors of 8.9 and 9.6 when comparing 
national data with true disease incidence for Thailand and Cambodia respectively [195, 218]. 
Moreover, a recent study of the global burden of dengue estimated that there are three times as 
many infections and dengue cases compared to cases reported to the World Health 
Organization [28].  
For most regions in the world with endemic dengue transmission we do not have 
accurate estimates of infection and disease because of the cost and infrastructure required to 
conduct cohort studies.  The most comprehensive cohort studies on dengue in South East Asia 
have been done in Thailand where the incidence of infection has ranged between 2 to 15% 
depending on the year and location of the study [141, 194, 196, 219, 220]. Studies in Puerto 
Rico, Nicaragua and Peru have documented incidences that range between 1.34-12% 
depending on the year and location [199, 200].  Thus, the intensity of dengue transmission 
among children in Colombo (8.14%) is similar to transmission documented in other cohort 
studies conducted in South East Asia and Latin America.  The ratio of inapparent to apparent 
infections has also been estimated in different regions of the world.  In southeast Asia the ratio 
has ranged from 3:1 to 1:1, whereas in Latin America the ratio has ranged from 3:1 to 18:1, 
indicating that infections in Southeast Asia [141, 194, 196] are more likely to lead to clinically 
apparent cases compared to infections in Latin America  [199, 200]. The data we report here 
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indicates that the situation in Colombo Sri Lanka with a ratio of 1.5:1 is more similar to the 
situation in Southeast Asia. 
The current study was not designed to test hypotheses about risk factors for DHF/DSS 
because our cohort of 799 children is too small to detect significant numbers of DHF/DSS 
cases. We did not observe any significant differences in the ratio of inapparent to apparent 
cases between primary and secondary cases.  However, it is premature to conclude from these 
data that risk of developing a clinically apparent infection is the same in primary and secondary 
cases as the study was only powered to detect a large difference in risk following primary and 
secondary infection.  We do note that other studies have documented that children exposed to 
primary and secondary infections have a similar risk of developing clinically apparent infections 
[194].  
It is well documented that the incidence of infection and disease can vary from year to 
year and our data was collected over a single year only.   Our study was confined to a relatively 
small area and our results may not be generalizable to children in other parts of the city and 
country.  Thus, studies such as this have to be conducted in other parts of the country over a 
longer period to understand how the incidence of infection and disease vary by location and 
over time.  Dengue vaccines are currently being tested in different regions of the world [162].  It 
is important that trials also be conducted in the Indian subcontinent given the heavy burden of 
disease and the distinct strains of DENV circulating in the region.  The results of the current 
study will be useful for designing vaccine trials in the region of South Asia and for making 
decisions about how best to introduce vaccines.    
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Table 2.1. Detection of secondary inapparent dengue cases by 2-dilution neutralization  
screen5 
 
                                                          
5Children were screened for increased neutralization activity against DENV1-4 over the study 
period. Paired baseline and follow-up sera at dilutions of 1:40 and 1:640 were subjected to 
neutralization tests 
   
Neutralization Capacity (% of virus) 
 
Serum Dilution 
DENV1 DENV2 DENV3 DENV4 Detected 
by Neut 
Screen 
(N) 
50 70 90 50 70 90 50 70 90 50 70 90 
N
o
t 
 
In
fe
c
te
d
 
Baseline 
1:40 - - - + + + - - - - - - 
421 
1:640 - - - - - - - - - - - - 
Follow-up 
1:40 - - - + + + - - - - - - 
1:640 - - - - - - - - - - - - 
S
e
c
o
n
d
a
ry
 
In
a
p
p
a
re
n
t 
Baseline 
1:40 + - - + - - + + - - - - 
20 
1:640 - - - - - - - - - - - - 
Follow-up 
1:40 + + + + + - + + - + - - 
1:640 + + - + + - + + + - - - 
 
`    441 
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Table 2.2. Ability of IgG ELISA to detect true dengue infections based on neutralization 
assay outcome6 
 
 Neutralization Assay Outcome7 
 
 Primary Cases Predictive 
Values (%) 
Secondary Cases 
Predictive 
Values (%) (+) (-) (+) (-) 
IgG 
ELISA 
Outcome8 
(+) 339 1010 76.7%11 209 4710 29.9%11 
(-) 212 31313 99.4%14 1212 36213 96.8%14 
 Sensitivity Specificity  Sensitivity Specificity  
94.3%15 96.9%16 62.5% 88.5%  
 
  
                                                          
6Paired baseline and follow-up samples were subjected to DENV IgG ELISA and DENV 
neutralization assay. 
 
7Neutralization assay outcome criteria: A primary case was DENV seronegative at baseline and 
DENV seropositive at follow-up. A secondary case was DENV seropositive at baseline and 
indicated a 2-fold neut50 titer increase or seroconversion to at least one DENV serotype at 
follow-up.  
 
8IgG ELISA outcome criteria: A primary case was DENV IgG negative at baseline and DENV 
IgG positive at follow-up. A secondary case was DENV IgG positive at baseline and showed an 
increase in DENV IgG OD at follow-up.  
 
9True Positive (TP) – correctly identified 
 
10False Negative (FN) – incorrectly identified 
 
11Positive Predictive Value (PPV) – [TP ÷ (TP+FP) × 100%] 
 
12True Negative (TN) – correctly unidentified 
 
13False Positive (FP) – incorrectly identified 
 
14Negative Predictive Value (NPV) – [TN ÷ (FN+TN) × 100%] 
 
15Sensitivity – [TP / (TP + FN) × 100%] 
 
16Specificity – [TN / (TN + FP) × 100%] 
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Table 2.3. Age-specific dengue sero-prevalence17 
Age group 
(years) 
No. 
children 
No. seropositive 
by IgG ELISA 
No.  seropositive 
confirmed by dengue 
neutralization test Seroprevalence (%) 
0 51 12 11 21.57 
1-3 196 71 67 34.18 
4-6 191 105 100 52.36 
7-9 225 150 145 64.44 
10-12 136 103 101 74.26 
Total (0-12) 799 441 424 53.07 
                                                          
17The dengue seroprevalence at the beginning of study (baseline) was determined by screening 
all sera by dengue IgG ELISA and then testing the positive samples by dengue neutralization 
test. 
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Table 2.4.  Age-specific fever episodes and incidence of dengue infection and illness18 
Age 
(yrs) 
 
# 
Children 
Fever Episodes New dengue infections 
Incidence of Infection  
(per 100 children) 
Incidence of Disease  
(per 100 children) 
Total Mean/Child Total Inapparent Apparent (95% confidence interval) 
0 51 31 0.6 1 0 1 1.96 (0.05-10.45) 1.96 (0.05-10.45) 
1-3 196 252 1.3 27 15 12 13.78 (9.28-19.41) 6.12 (3.20-10.45) 
4-6 191 174 0.9 13 11 2 6.81 (3.67-11.36) 1.05 (0.13-3.73) 
7-9 225 137 0.6 15 6 9 6.67 (3.78-10.76) 4.00 (1.85-7.46) 
10-12 136 87 0.6 11 8 3 8.09 (3.25-16.03) 2.21 (0.46-6.31) 
0-12 799 681 0.9 67 40 27 8.39 (6.56-10.53) 3.38 (2.24-4.88) 
 
 
  
                                                          
18Clinically apparent dengue infections were diagnosed by performing paired serology and PCR on acute and convalescent samples 
collected from febrile children.  Total dengue infections over the study year were detected by testing paired baseline and end of year 
samples by IgG ELISA and neutralization test. Children who were infected but not identified as apparent cases were designated as 
inapparent cases. 
 41 
 
Table 2.5. Dengue disease outcome in children exposed to primary versus secondary 
infections 
  Disease 
Infection Total Inapparent Apparent Inapp./App. ratio 
Primary 35 20 15 1.33 
Secondary 32 20 12 1.67 
Total 67 40 27 1.48 
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Table 2.6. Prevalence of circulating DENV serotypes 
 DENV Serotype Exposure 
(before initiation of study)19 
N (%) 
DENV Serotype Exposure 
during study year20 
N (%) 
DENV1 7 (9) 7 (21) 
DENV2 32 (43) 16 (49) 
DENV3 27 (36) 9 (27) 
DENV4 9 (12) 1 (3) 
Total 75 (100) 33 (100) 
 
  
                                                          
19A dengue immune individual was considered to have been previously exposed to a particular 
serotype if the individual had neutralizing antibodies to one serotype only (monotypic) at 
baseline. Inferences of infecting serotype were not made when more than one serotype was 
neutralized.  
 
20Based on children who were exposed to primary infections during the study year. The 
serotype was determined by PCR or neutralization test performed with sample collected at the 
end of the study (follow-up).  
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Figure 2.1. Map and location of study site (Ward 33) in relation to Colombo Municipal 
Council and Colombo District in Sri Lanka. 
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Figure 2.2. Representative neutralization curves for confirmed inapparent dengue cases. 
Graph shows representative cases. Paired baseline (A,C)  and follow-up sera (B,D) (when 
available) from 1° (A-B) and 2° (C-D) dengue cases  were subjected to neutralization assay at 
1:40 – 1:10240 in 4-fold increments against DENV1-4.  Sigmoidal curves were generated, and 
neut50 titers were calculated for each serotype. These graphs depict temporal sera collected 
from two representative children (1 primary and 1 secondary). 
 
  
 45 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER THREE 
  
Temporal Regulation of Antibody Responses Following Dengue Virus Infections 
in a Sri Lankan Pediatric Cohort 21 22 
 
3.1 Introduction  
Dengue virus (DENV) is a positive-stranded RNA virus that is transmitted to humans via 
the bite of Aedes mosquitos. DENVs exist as four serotypes, DENV1-4, which circulate in 
tropical and subtropical regions.  Currently, over 2/3 of the world’s population is at risk of being 
exposed to DENV [21, 22]. A recent study estimates 390 million DENV infections occur globally 
each year, rendering dengue the most common mosquito-borne human virus in the world [28].  
An individual can be infected and re-infected with DENV. Primary (1°) dengue infection 
occurs when a naïve individual is exposed to DENV. Repeat dengue infection occurs when a 
previously-exposed individual is exposed to DENV for the second (secondary), third (tertiary), or 
fourth (quaternary) time, etc. Natural human DENV infection can result in clinically inapparent or 
apparent infections. Apparent infections, which account for less than half of total DENV 
infections, manifest as mild dengue fever (DF), severe dengue hemorrhagic fever (DHF), or 
potentially fatal dengue shock syndrome (DSS) [28].  
                                                          
21
Portions of this chapter are in press. | Corbett K.S., Katzelnick L, Tissera H, Amarasinghe A, de 
Silva A.D., and de Silva A.M., Pre-existing Neutralizing Antibody Responses Distinguish Clinically 
Inapparent and Apparent Dengue Virus Infections in a Sri Lankan Pediatric Cohort. Journal of Infectious 
Diseases. 
 
22
This study was funded by the Pediatric Dengue Vaccine Initiative (Bill and Melinda Gates Foundation 
Grant #: 23197). Additional funding was provided by UNC Virology Training Grant (NIH Grant #: 
T32AI007419) and Initiative for Minority Student Development (NIH Grant #: 5R25GM055336). 
 46 
 
Viral and host factors have been shown to influence dengue disease outcome [31, 38, 
42, 43]. But, the most significant risk factor for severe disease is previous DENV infection [69-
73]. Primary DENV infection induces cross-reactive non-neutralizing antibodies that assist in 
binding and uptake of DENV particles into FcᵞR-bearing cells upon secondary infection with a 
heterologous DENV serotype [69, 221]. This phenomenon is coined “antibody-dependent 
enhancement (ADE)” [221].  
Together, a compilation of recent studies suggests that the human DENV antibody 
response following primary DENV infection is dominantly cross-reactive and weakly neutralizing 
[81, 99, 222]. Current dogma suggests that following 1° DENV infections neutralizing antibodies 
are induced in two forms: long-lasting type-specific antibodies and short-lived cross-reactive 
neutralizing antibodies (reviewed in [115]), but the specifics of temporal regulation of antibody 
responses following dengue infections remain unclear. To that end, here we utilized sera 
samples collected during a prospective dengue fever surveillance study in Colombo, Sri Lanka 
[215, 216] to provide insight on the timing of IgG and neutralizing antibody responses following 
primary and repeat DENV infections.  
3.2 Materials and Methods 
Human Subjects Protocol Approval 
Ethical approval for this research was obtained from the Ethical Review Committee of 
the Faculty of Medicine, University of Colombo, Sri Lanka and the Institutional Research Board 
(IRB) of the International Vaccine Institute, Seoul, Korea. University of North Carolina IRB 
determined that this study does not constitute human subject research with respect to UNC 
investigators’ involvement. Only children whose parents or legal guardians provided written 
informed consent were enrolled in the study. 
Cell Lines and Viruses 
U937+DC-SIGN cells were maintained in RPMI media supplemented with 5% fetal 
bovine serum, 1% L-Glutamine, 1% Penicillin/Streptomycin, 1% non-essential amino acids, and 
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0.05 mM beta-mercaptoethanol. C6/36-derived WHO reference DENV strains, DENV1 (West 
Pac 74), DENV2 (S-16803), DENV3 (CH 53598), DENV4 (TVP-376), were used in all infection-
based experiments.  
Sample Collection  
Surveillance and sample collection methods were previously detailed [215, 216]. Briefly, 
between November 2008 and January 2010, in Colombo, Sri Lanka, blood samples were 
collected from 799 children, ≤ 12 years old, at enrollment (baseline) and 12 months later (follow-
up). In addition, children who experienced febrile illness were bled upon fever onset (acute) and 
≥ 10 days following fever dissipation (convalescent) [216]. Blood samples were stored as dried 
blood spots (DBS) on protein saver cards (Whatman, UK & ID Biological Systems, Greenville 
SC USA) [207, 208] or centrifuged and stored as plasma.  
Elution of Antibodies from DBS 
DBS diluent volume was determined based on standard plasma dilutions in pilot 
experiments using matched DBS and plasma obtained from our dengue traveler cohort [99]. 
Antibodies were eluted from DBS by submerging filter paper in diluent appropriate for 
subsequent assay. DBS/diluent mixtures were incubated at 37°C for 2hrs. Resulting DBS 
eluates (sera) were used in IgG, IgM, and neutralization assays, as described below.  
Detection of DENV-specific IgG and IgM Antibodies  
Immunoassays for detection of DENV-specific IgG and IgM antibodies were performed 
as previously described [31, 39]. Sera were used at 1:100 and 1:50 in IgG and IgM ELISAs, 
respectively. Cutoffs for IgM and IgG positivity were determined based on positive control 
samples and, where applicable, represented as standard deviations relative to normal human 
sera (NHS) controls (N = 10, pooled). 
Detection of DENV Neutralizing Antibodies  
Sera were assessed for the presence of neutralizing antibodies against each DENV 
serotype using a flow cytometry-based neutralization assay with U937 monocytic cells stably 
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transfected with DC-SIGN (U937+DC-SIGN), as previously described [213, 214]. Sera dilutions 
used were 1:40 – 1:10240 in 4-fold increments. Samples were run on GUAVA easyCyte HT and 
analyzed on GUAVASoft software (Millipore, Billerica MA USA).  Sigmoidal curves were 
generated using Prism v4.0 (GraphPad Software, La Jolla CA USA). Neut50 titer was calculated 
as the dilution of a serum that neutralizes 50% of each DENV serotype. The seroconversion 
threshold was set to ≥ 50% neutralization at ≥ 1:40 serum dilution.  
Laboratory Confirmation of DENV Infections 
 To identify clinically apparent DENV infections, acute and convalescent samples were 
collected from children with fever and tested by PCR and paired IgG and IgM serology, as 
previously described [216].  Refer to chapter two for complete details of how inapparent DENV 
infections were detected. Briefly, all children were screened for increases in neutralizing 
antibody levels over the study year by testing paired baseline and 12-month follow up samples 
(at dilutions of 1:40 and 1:640) by neutralization assay (Table 2.1). Cases were then confirmed 
by neutralization assay with full serum dilution series (Figure 2.2). DENV infections occurring in 
children who did not have a laboratory-confirmed apparent dengue fever during the study year 
were classified as inapparent DENV infections. Dengue cases were further classified as primary 
or secondary based on baseline DENV naïve or immune status, respectively. Notably, all DENV 
cases in this study were confirmed by gold-standard neutralization assay [213, 214].   
Statistical Analyses  
To compare DENV IgG levels or neut50 titers between inapparent and apparent groups, 
we used unpaired student’s t-tests. Unpaired student’s t-tests were also used to compare neut50 
titers between IgM- and IgM+ groups. Repeated measure 1-way ANOVA with Tukey’s multiple 
comparison post-test analysis was used to compare DENV IgG levels of paired baseline, acute, 
convalescent, and follow-up groups. To compare breadth of neutralizing antibody responses 
between groups, we performed Fisher’s exact tests, defining outcome categories as “monotypic” 
(seroconversion to one serotype) and “heterotypic” (seroconversion to ≥ 2 serotypes). Pearson’s 
 49 
 
product-moment correlation tests were used to determine the linear relationship between 
elapsed time and neutralization breadth or magnitude. A 1-way ANOVA, with Tukey’s multiple 
comparison post-test, was used to compare mean # of serotypes neutralized or mean neut50 
titer at baseline, acute, convalescence, and follow-up for 2° apparent cases. For some assays, 
sample variability exists due to the limited quantity of sample available for the multiple and 
repeat analysis of the various assays, not due to loss at follow-up. P-values represent two-tailed 
analyses, unless otherwise specified. On graphs, each dot shows an individual serum sample 
measured in duplicate, and, wherever applicable, means are depicted. Generation of graphs 
and statistical analyses was completed using Prism v4.0. 
3.3 Results 
We used blood samples from a prospective pediatric dengue cohort study in Colombo, 
Sri Lanka to describe temporal regulation antibody responses in children who acquired primary 
and secondary dengue infections. The cohort population, study design, surveillance methods, 
and epidemiological findings are detailed elsewhere [215, 216].  As previously reported, we 
identified a total of 35 primary and 32 secondary/repeat infections over the 12-month study 
period (Table 2.1) [216]. Forty of the infections (20 primary and 20 secondary/repeat) were 
classified as inapparent, as they occurred in children who did not have a laboratory-confirmed 
dengue fever during the 12 month period of active disease surveillance.  
Comparison of antibody responses following primary inapparent and apparent DENV 
infections 
 
First, we set out to compare acquired DENV-specific antibody responses in children 
exposed to 1° inapparent and apparent infections.  We found no difference in total DENV-
binding IgG (Figure 3.1A) or the ability of antibodies to neutralize the 4 DENV serotypes 
(Figure 3.1B,C).  Both 1° inapparent and apparent DENV infections induced neutralizing 
antibody responses that were monotypic in some cases and heterotypic in other cases (Figure 
3.1B). The magnitude of neutralization, as depicted by combined 50% neutralization across all 
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DENV serotypes, induced by 1° inapparent and apparent DENV infections was also similar 
(Figure 3.1C). Together, these data indicate that children experiencing 1° inapparent and 
apparent infections develop similar DENV-specific antibody responses; thus regulation of 
antibody responses following primary infection must be correlated with another factor, such as 
time or genetics.  
Temporal analysis of antibody responses following primary DENV infections 
Therefore, we went on to characterize temporal regulation of neutralizing antibody 
responses following primary DENV infections. With apparent infections, for which we knew the 
date of fever onset, we found a significant negative correlation between time elapsed after 
infection and neutralization breadth across the 4 serotypes (Pearson’s r = -0.69, P < 0.01); 
children who experienced recent dengue fever had more broadly neutralizing antibody 
responses than children who experienced dengue fever early in the study year (Figure 3.2A). 
Although there was a trend towards a negative correlation between time elapsed after 1° 
apparent infection and neutralization magnitude, it was not statistically significant (Figure 3.2C).  
 Following these observations, for all 1° infections, both inapparent and apparent, we 
tested follow-up sera for presence of DENV IgM, which are indicative of recent (<6 months) 
infection [112]. Serotype cross-neutralizing sera were more likely to be IgM-positive than 
monotypic sera (P < 0.05) (Figure 3.1B) further confirming the association between recent 
primary exposure and broad neutralization. Additionally, IgM-positive sera have a significantly 
higher neutralization magnitude than IgM-negative sera (P < 0.01) (Figure 3.2D). Together, 
these data indicate that 1° DENV infection stimulates a DENV-serotype cross neutralizing 
response that evolves over time into a more monotypic response.     
Temporal analysis of antibody responses following repeat DENV infections 
Seeing temporal changes in antibody responses following primary infections, we set out 
to measure changes in DENV-specific antibodies as a function of time following repeat DENV 
infections.  We focused on apparent infections for which dates of actual infection were known. 
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There was a significant increase in DENV IgG at the early convalescent stage (~2-4 weeks after 
infection), compared to baseline (p < 0.001) and acute stages (p < 0.05). However, these 
elevated IgG levels had declined back to pre-infection and acute levels by the end of the study 
year (follow-up) (Figure 3.3A).  Neutralization curves of timed sera from apparent re-infections 
revealed boosting of neutralizing antibody titer against the serotype of previous infection (data 
not shown). At the convalescent stage, there was a robust increase in neutralizing antibody titer 
against multiple DENV serotypes, compared to baseline (P < 0.001) (Figure 3.3B,C).  Although 
the overall magnitude of neutralizing antibody was slightly reduced at follow-up, the response 
remained broadly cross neutralizing (Figure 3.3B,C). Our complete analysis of neutralization 
breadth in apparent repeat infections revealed a significant and stable increase in neutralization 
breadth that was maintained through the end of the study (follow-up) compared to pre-infection 
(baseline)  (p < 0.001) and acute (p < 0.05) levels (Figure 3.3C).  Thus, for repeat infections, 
although the overall quantity of DENV-specific IgG antibody increased and then decreased back 
to pre-infection/acute levels, the magnitude and breath of neutralization was increased and 
maintained over the duration of the study year.   
3.4 Discussion  
In this study, we used blood samples collected from a Sri Lankan pediatric dengue 
cohort to investigate temporal regulation of antibody responses in children exposed to 
inapparent and apparent DENV infections. With respect to primary DENV infections, factors 
other than pre-existing immunity, such as infecting DENV strain or serotype and/or intrinsic host 
factors, must influence development of inapparent versus apparent infection [41, 141, 223, 224].  
Here, we explored whether inapparent and apparent primary infections stimulated different 
antibody responses in children and found no differences in DENV-specific IgG or neutralization 
quality.  
Our data also demonstrates that time elapsed following primary DENV infections 
negatively correlates with breadth of neutralization, suggesting that neutralizing antibody 
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responses evolve from cross-neutralizing to serotype-specific by 8-12 months after infection. 
Others have also observed that primary DENV exposure results in cross-neutralizing/protective 
antibodies that gradually become monotypic as time elapses [106, 222, 225], although 
mechanisms responsible for the waning of cross-neutralization following primary DENV 
infections have not been defined.  We utilized IgM as a marker of time in those children who got 
inapparent infections for which we did not know the specific date of infection. In doing so, we 
observed a strong association between the presence of DENV-specific IgM and cross 
neutralization, further associating recent infections with broad neutralization. This data also 
indicates that IgM may, in part, be responsible for cross neutralization. However, IgM cannot be 
the only explanation because the period of transient cross neutralization extends to 8-12 
months, which is well beyond the 3-6 month window after infection when IgM is detected. The 
magnitude of the neutralization response following primary infections did not wane significantly 
over time as breadth did, but we saw significantly higher neutralization titers in IgM-positive sera 
than IgM-negative sera. This alludes to IgM being partially responsible for high neutralization 
titers following primary infection, similar to a previous study conducted by the Harris group [113], 
but further studies are needed to understand what role, if any, IgM antibodies have in 
neutralization and protection. 
For repeat apparent infections, we were able to characterize antibody quantity and 
quality before, during, and after infection.  Although we did not observe a significant rise in 
DENV-specific IgG during the acute stage of infection, by 2-4 weeks after infection most 
children had elevated levels of IgG compared to pre-infection levels.  Surprisingly, the elevation 
of IgG after repeat infection was not stable; in fact, when follow-up samples were collected 
several months after re-infection, IgG levels had declined to pre-infection and acute levels.  At 
the acute stage, we observed boosting of neutralizing antibody response to previously-infecting 
serotype in most repeat infection cases. At 2-4 weeks after a repeat infection, children had high 
levels of cross-neutralizing antibodies.  When follow-up samples were collected several months 
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later, although the overall magnitude of neutralizing antibody had slightly decreased (though not 
significantly), the breath of neutralizing antibody remained significantly greater than in the pre-
repeat infection sample.  We did not follow these children longer than 12 months, but we believe 
that these cross-neutralizing antibody responses are long-lived, perhaps for a lifetime. Thus, 
although following a repeat DENV infection, the quantity of DENV-specific IgG returned to pre-
infection/acute levels, the quality of the neutralization response was stably altered. Our findings 
show that antibody responses following primary and repeat infections are temporally regulated 
in different ways. Understanding how the temporal regulation of these antibody responses 
correlates with protection from subsequent DENV infection or disease will be important for 
DENV vaccine development. 
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Figure 3.1. Comparison of antibody responses following primary inapparent and 
apparent dengue virus infections. Follow-up sera from children exposed to 1° DENV 
infections were subjected to (A) IgG ELISA at 1:100 dilution and (B-C) neutralization assays at 
1:40 – 1:10240 in 4-fold increments against DENV1-4. (A) Lines represent mean OD405nm 
values. Means were found to be insignificant by unpaired student’s t-test. (B-C) Sigmoidal 
curves were generated, and neut50 titers were calculated for each serotype. (B) 
Neutralization/Seroconversion threshold was set to ≥ 50% neutralization at ≥ 1:40 serum dilution 
for each DENV serotype. Groups were compared using Fisher’s exact tests, defining outcome 
categories as “monotypic” (seroconversion to one serotype) and “heterotypic” (seroconversion 
to ≥ 2 serotypes). (C) Total neut50 is a calculation of each serum’s combined neut50 titer across 
all serotypes. Lines represent mean total neut50 values for each group and were found to be 
insignificant by unpaired student’s t-test. (A-C) Each dot represents mean values of an 
individual serum tested in duplicate.  
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Figure 3.2. Temporal analysis of neutralizing antibody responses following primary 
dengue virus infections. Follow-up sera from children exposed to 1° DENV infections were 
subjected to neutralization assays at 1:40 – 1:10240 in 4-fold increments against DENV1-4. 
Sigmoidal curves were generated, and neut50 titers were calculated for each serotype. 
Neutralization/Seroconversion threshold was set to ≥ 50% neutralization at ≥ 1:40 serum dilution 
for each DENV serotype. Neut50 is a calculation of each serum’s combined neut50 titer across 
(C,D) all serotypes, (C) the three heterologous serotypes, which were not responsible for 
infection, or the infecting serotype, as determined by PCR or serotype of highest neutralization 
response. (B,D) Those sera were also subjected to IgM ELISA at 1:50 dilution; IgM positivity 
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was determined to be 5 standard deviations over NHS (N=10, pooled). (A,C) For 1° apparent 
infections, time elapsed since DENV fever was determined as amount of time between date of 
acute fever onset and date of follow-up sample collection. Line was generated by linear 
regression analysis. Correlation between (A) neutralization breath or (C) neutralization 
magnitude and elapsed time was calculated by Pearson’s product-moment correlation test. (B) 
Groups were compared using Fisher’s exact tests, defining outcome categories as “monotypic” 
(seroconversion to one serotype) and “heterotypic” (seroconversion to ≥ 2 serotypes). (D) Lines 
represent mean total neut50 values for each group and were compared using unpaired student’s 
t-test. (A-D) Each dot represents mean values of an individual serum tested in duplicate. 
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Figure 3.3. Temporal analysis of antibody responses following repeat dengue virus 
infections. Paired baseline, acute, convalescent, and follow-up sera (when available) from 
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repeat apparent DENV infections were subjected to (A) IgG ELISA at 1:100 dilution, and (B,C) 
neutralization assay at 1:40 – 1:10240 in 4-fold increments against DENV1-4.  (A) DENV IgG 
OD values were calculated as fold change with respect to baseline OD values. (B-C) Sigmoidal 
curves were generated, and neut50 titers were calculated for each serotype. (B) Total Neut50 is a 
calculation of each serum’s combined neut50 titer across all serotypes. (C) The 
neutralization/seroconversion threshold was set to ≥ 50% neutralization at ≥ 1:40 serum dilution 
for each DENV serotype. (A-C) Each dot represents mean values of an individual serum tested 
in duplicate. Lines show (A) mean OD values, (B) mean total neut50 values, and (C) # of DENV 
serotypes neutralized at each timepoint; timepoints were compared by 1-way ANOVA, with 
Tukey’s multiple comparison post-test.  
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CHAPTER FOUR 
Pre-existing Neutralizing Antibody Responses Distinguish Clinically Inapparent 
and Apparent Dengue Virus Infections in a Sri Lankan Pediatric Cohort23 24 
 
4.1 Introduction 
The most significant risk factor for severe disease is previous DENV infection; an 
individual experiencing secondary (2°) infection with a heterologous DENV serotype faces 
greater risk of developing severe disease than someone experiencing primary (1°) infection [69-
73]. Antibody dependent enhancement (ADE) is the leading explanation for increased severe 
dengue disease risk following re-infection. ADE theory postulates that 1° DENV infection 
induces cross-reactive non-neutralizing antibodies that promote entry of DENV particles into 
FcᵞR-bearing cells upon 2° infection with a heterologous DENV serotype. This phenomenon is 
believed to result in increased cellular viral burden and subsequent severe disease [80, 150, 
221]. 
Many studies have been performed to examine the role of antibodies in severe dengue 
disease [78, 128, 149-152]. A topic that has been less studied is the role of antibodies in 
clinically inapparent versus apparent DENV infection [38, 113, 116]. The mere fact that 75% of 
DENV infections occur subclinically in populations where repeat infections are highly likely [28] 
points to an important role for neutralizing antibodies in protection from repeat apparent 
infections. In fact, progression to or protection from dengue disease is likely dependent on the 
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balance between DENV enhancing and neutralizing antibodies [128]. Here we set out to test the 
hypothesis that antibody responses are linked to the development of inapparent and apparent 
DENV infections. We did so by utilizing sera collected from naturally-infected children in a 
prospective dengue fever surveillance cohort study in Colombo, Sri Lanka [216]  
4.2 Materials and Methods 
Human Subjects Protocol Approval 
Ethical approval for this research was obtained from the Ethical Review Committee of 
the Faculty of Medicine, University of Colombo, Sri Lanka and the Institutional Research Board 
(IRB) of the International Vaccine Institute, Seoul, Korea. University of North Carolina IRB 
determined that this study does not constitute human subject research with respect to UNC 
investigators’ involvement. Only children whose parents or legal guardians provided written 
informed consent were enrolled in the study. 
Cell Lines and Viruses 
U937+DC-SIGN cells were maintained in RPMI media supplemented with 5% fetal 
bovine serum (FBS), 1% L-Glutamine (L-Gln), 1% Penicillin/Streptomycin (Pen/Strep), 1% non-
essential amino acids (NEAA), and 0.05 mM beta-mercaptoethanol. K652 cells were maintained 
in RPMI media supplemented with 5% FBS, 1% L-Gln, 1% Pen/Strep, and 1% NEAA. C6/36-
derived WHO reference DENV strains, DENV1 (West Pac 74), DENV2 (S-16803), DENV3 (CH 
53598), DENV4 (TVP-376), were used in all infection-based experiments.  
Sample Collection  
Surveillance and sample collection methods were previously detailed [215, 216]. Briefly, 
between November 2008 and January 2010, in Colombo, Sri Lanka, blood samples were 
collected from 799 children, ≤ 12 years old, at enrollment (baseline) and 12 months later (follow-
up). In addition, children who experienced febrile illness were bled upon fever onset (acute) and 
≥ 10 days following fever dissipation (convalescent) [216]. Blood samples were stored as dried 
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blood spots (DBS) on protein saver cards (Whatman, UK & ID Biological Systems, Greenville 
SC USA) [207, 208] or centrifuged and stored as plasma.  
Elution of Antibodies from DBS 
DBS diluent volume was determined based on standard plasma dilutions in pilot 
experiments using matched DBS and plasma obtained from our dengue traveler cohort [99]. 
Antibodies were eluted from DBS by submerging filter paper in diluent appropriate for 
subsequent assay. DBS/diluent mixtures were incubated at 37°C for 2hrs. Resulting DBS 
eluates (sera) were used in IgG, IgM, and neutralization assays, as described below.  
Detection of DENV-specific IgG and IgM Antibodies  
Immunoassays for detection of DENV-specific IgG and IgM antibodies were performed 
as previously described [31, 39]. Sera were used at 1:100 and 1:50 in IgG and IgM ELISAs, 
respectively. Cutoffs for IgM and IgG positivity were determined based on positive control 
samples and, where applicable, represented as standard deviations relative to normal human 
sera (NHS) controls (N = 10, pooled). 
Detection of DENV Neutralizing Antibodies  
Sera were assessed for the presence of neutralizing antibodies against each DENV 
serotype using a flow cytometry-based neutralization assay with U937 monocytic cells stably 
transfected with DC-SIGN (U937+DC-SIGN), as previously described [213, 214]. Sera dilutions 
used were 1:40 – 1:10240 in 4-fold increments. Samples were run on GUAVA easyCyte HT and 
analyzed on GUAVASoft software (Millipore, Billerica MA USA).  Sigmoidal curves were 
generated using Prism v4.0 (GraphPad Software, La Jolla CA USA). Neut50 titer was calculated 
as the dilution of a serum that neutralizes 50% of each DENV serotype. The seroconversion 
threshold was set to ≥ 50% neutralization at ≥ 1:40 serum dilution.  
Detection of DENV Enhancing Antibodies  
The presence of DENV enhancing antibodies in sera was determined using a flow 
cytometry-based enhancement assay with FcγRIIa+ K562 erythroleukemic cells, as previously 
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described [226]. RPMI media supplemented with 2% FBS, 1% L-Gln, 1% Pen/Strep, and 1% 
NEAA was used for this assay. 1:40 dilution of sera and each DENV serotype was incubated at 
37°C for 1 hour. Virus was added at an MOI of 1, based on titers calculated in Vero81 cells. 
Cells were added to sera/DENV mixtures and incubated at 37°C for 2 hours. Cells were washed 
in media twice and incubated at 37°C for 24 hours (from the time of cells being added). As 
previously described with our flow cytometry based neutralization assay [213, 214], cells were 
then washed, fixed, permeabilized, and stained with 2H2-Alexa488 to detect DENV-infected 
cells. 2H2-Alexa488 is a flavivirus prM-specific antibody conjugated to Alexa488. Samples were 
run on GUAVA easyCyte HT and analyzed on GUAVASoft software (Millipore, Billerica MA 
USA).  Percentage of infection was determined. On graphs, % infection is represented at 
number of standard deviations (SD) above mean % infection of NHS (N=10). Enhancement 
threshold was set to ≥ 10 SD above mean % infection of NHS (N=10), based on positive 
controls (N=3) for each DENV serotype. 
Laboratory Confirmation of DENV infections 
 To identify clinically apparent DENV infections, acute and convalescent samples were 
collected from children with fever and tested by PCR and paired IgG and IgM serology, as 
previously described [216].  Refer to chapter two for complete details of how inapparent DENV 
infections were detected. Briefly, all children were screened for increases in neutralizing 
antibody levels over the study year by testing paired baseline and 12-month follow up samples 
(at dilutions of 1:40 and 1:640) by neutralization assay (Table 2.1). Cases were then confirmed 
by neutralization assay with full serum dilution series (Figure 2.2). DENV infections occurring in 
children who did not have a laboratory-confirmed apparent dengue fever during the study year 
were classified as inapparent DENV infections. Dengue cases were further classified as primary 
or secondary based on baseline DENV naïve or immune status, respectively. Notably, all DENV 
cases in this study were confirmed by gold-standard neutralization assay [213, 214].   
 
 63 
 
Statistical Analyses  
To compare DENV IgG levels or neut50 titers between inapparent and apparent groups, 
we used unpaired student’s t-tests. To compare breadth of neutralizing antibody responses 
between groups, we performed Fisher’s exact tests, defining outcome categories as “monotypic” 
(seroconversion to one serotype) and “heterotypic” (seroconversion to ≥ 2 serotypes). 
Enhancement of inapparent and apparent groups were compared for each DENV serotype by 
Mann Whitney test. Neutralization and enhancement were correlated using Pearson’s product 
moment correlation tests. In the quantitative analysis of neutralization breadth, represented in 
table 4.1, Wilcoxon rank sum test was used for statistical comparison between groups, as 
samples were not normally distributed. For some assays, sample variability exists due to the 
limited quantity of sample available for the multiple and repeat analysis of the various assays, 
not due to loss at follow-up. P-values represent two-tailed analyses, unless otherwise specified. 
On graphs, each dot shows an individual serum sample measured in duplicate, and, wherever 
applicable, means are depicted. Generation of graphs and statistical analyses was completed 
using Prism v4.0. 
4.3 Results 
We used blood samples from a prospective pediatric dengue cohort study in Colombo, 
Sri Lanka to compare pre-existing antibody responses between children who developed repeat 
clinically inapparent and apparent dengue infections.  The cohort population, study design, 
surveillance methods, and epidemiological findings are detailed elsewhere [215, 216].  As 
previously reported, we identified a total of 35 primary and 32 secondary/repeat infections over 
the 12-month study period (Table 2.1) [216]. Forty of the infections (20 primary and 20 
secondary/repeat) were classified as inapparent, as they occurred in children who did not have 
a laboratory-confirmed dengue fever during the 12 month period of active disease surveillance.  
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Comparison of pre-existing neutralizing antibody responses of repeat inapparent and 
apparent DENV infections 
 
To compare pre-existing (baseline) antibody responses of children experiencing repeat 
inapparent and apparent infections, we first looked at total DENV-specific IgG levels and found 
no difference (Figure 4.1A). Then, we compared the magnitude and breadth of pre-existing 
neutralizing antibody responses. Total 50% neutralization titers, across all DENV serotypes, did 
not differ (Figure 4.1B). However, we found that children who got repeat inapparent DENV 
infections were more likely to have heterotypic neutralizing responses at baseline compared to 
children who got repeat apparent infections (p < 0.05) (Figure 4.1C). To examine whether 
children who got repeat inapparent infections had experienced very recent past DENV 
infections, we tested pre-infection sera for the presence of DENV-specific IgM. We did not 
observe a correlation between the presence of IgM and neutralization breadth or clinical 
outcome (Figure 4.1D). In fact, 17 out of the 20 (85%) baseline sera from children who had 
inapparent repeat infections were DENV IgM-negative, indicating their prior DENV exposures 
had not occurred in the past 6 months. These data indicate that neutralization breadth of pre-
infection antibodies has significant bearing on clinical outcome of subsequent DENV infection. 
Furthermore, the difference in neutralization capacity observed comparing repeat inapparent 
and apparent infections cannot simply be explained by very recent exposure, based on IgM 
presence.  
Comparison of pre-existing enhancing antibody responses of repeat inapparent and 
apparent DENV infections 
  
Showing a difference in pre-existing neutralization capacity between repeat inapparent 
and apparent DENV infections, we wanted to determine if there was a difference in 
enhancement ability as well. We saw no difference in the ability of pre-existing antibodies from 
repeat inapparent and apparent DENV infections to enhance any of the DENV serotypes 
(Figure 4.2A). Because it believed that a balance between enhancing and neutralizing 
antibodies influences dengue disease outcome, we wanted to compare pre-existing 
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neutralization to enhancement. Overall, comparing breadth of neutralization to breadth of 
enhancement, we saw a correlation that was slightly negative but not significant, with a p-value 
of 0.07 (Figure 4.2B). There was a slight opposite relationship between the number of 
serotypes a child neutralized with the number of serotypes that child enhanced. Suspecting 
actual levels of neutralization and enhancement may be more telling, we compared pre-existing 
neutralization magnitude to enhancement magnitude. For each serotype, with the exception of 
DENV4, there was a negative correlation between neutralization and enhancement magnitudes 
(DENV1, p < 0.05 | DENV2, p < 0.001 | DENV3, p < .001) (Figure 4.2C-F). For DENV1-3, the 
higher a serum’s pre-existing neutralization titer, the weaker that serum’s ability to enhance the 
same serotype. These data indicate that enhancing ability of pre-infection antibodies does not 
have significant bearing on fever outcome of subsequent DENV infection, in the way that 
neutralization breadth does.  
Quantitative analysis of differences in neutralizing antibody responses between types 
We conducted a direct analysis of the difference in neutralization of DENV types to delve 
further into neutralizing antibody responses in the cohort (Table 4.1).  Breadth of response was 
measured as the difference between the titer of the dominantly neutralized DENV type, 
assumed to be of the previous infecting type, and the other three types. Similar to our 
aforementioned findings, we determined that children experiencing repeat apparent DENV 
infections had more monotypic baseline neutralizing antibody responses (dominant responses 
to a single DENV serotype) than those who acquired repeat inapparent infections (p < 0.05). 
Interestingly, a significant difference in post-infection breadth was also observed between 
inapparent and apparent repeat infections; apparent infections were observed to develop more 
balanced responses following infection than inapparent infections (p < 0.05).  Thus, children 
whose repeat infections were inapparent had relatively conserved patterns of neutralization at 
baseline and follow-up, while children whose repeat infections were apparent transitioned from 
mostly type-specific neutralization before infection to broad neutralization after their repeat 
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DENV exposure. The degree of breadth in this sample was independent of the magnitude of the 
best neutralized DENV type prior to infection.  Further, inapparent and apparent repeat 
infections had similar maximum titers at baseline and follow-up.  Notably, after the study year, 
both inapparent and apparent repeat infections had higher titers when compared with primary-
infected children (p < 0.05).   
4.4 Discussion 
Many studies have focused on how antibodies may enhance DENV infections and 
increase risk of developing DHF [78, 128, 149-152].  While it is well documented that most 
DENV infections are clinically-inapparent [28], factors responsible for inapparent infections have 
not been thoroughly investigated.  Here, we quantified the magnitude and relative breadth of 
neutralization before repeat infections. While pre-existing neutralization magnitude did not seem 
to affect dengue disease outcome, we observed a strong association between breadth of 
neutralization and manifestation of fever. Children who got repeat inapparent infections had 
more broadly-neutralizing pre-existing DENV antibodies than children who got apparent re-
infections. This is perhaps the most interesting finding of this study. It demonstrates an 
association between breadth of pre-existing DENV neutralizing antibodies and the likelihood of 
developing an inapparent versus apparent infection; thus, alluding to an important role of pre-
existing neutralizing antibodies in protection from clinical symptom manifestation in repeat 
dengue infections.  
There are different non-exclusive possible explanations for this association.  Recent 
studies based on careful analysis of serial first, second, and third DENV infections in Nicaragua 
and models based on large dengue data sets from Thailand indicate that the period of cross 
protection after a primary infection can be up to 2 years after infection [121, 227]. Children in our 
study who had secondary inapparent infections may have been more recently exposed to their 
first infection compared to children who had secondary apparent infections. Our data showing 
IgM absence in baseline samples of nearly all repeat infections (both inapparent and apparent) 
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demonstrates that these cases were not in children within the first 6 months of their first 
infection. It remains possible that children who had secondary inapparent infections were still 
within the 1-2 year window of cross-protection unlike children who had secondary apparent 
infections who were well beyond this period of cross protection.   
Another possibility is that children experiencing repeat apparent infections were exposed 
to secondary infections whereas most inapparent cases resulted from tertiary or quaternary 
(post-secondary) exposure. Thus, the broadly neutralizing baseline responses may be due to 2 
or more previous DENV infections whereas the children with monotypic responses may have 
only been exposed to a single serotype. Indeed, a recent study utilizing cohort samples from 
Iquitos, Peru demonstrated that individuals experiencing post-secondary infections were more 
likely to develop inapparent infections compared to people exposed to “true” second infections 
[116]. It is worthwhile to note that while it is possible that children who appeared to have 
inapparent second infections were actually having post-secondary infections, the degree of 
neutralization breadth we observed prior to infection in those cases was not significantly 
different from children with primary infections (Table 4.1).  It is likely that proximity to previous 
infection and number of previous infections, together with person-to-person variation, all 
influence whether someone will experience inapparent or apparent DENV re-infection.  
We explored the balance of neutralization and enhancement and found that magnitude 
of neutralization to DENV1-3 was negatively correlated with magnitude of enhancement 
responses. However, children who got repeat inapparent and apparent infections had similar 
levels of pre-existing DENV enhancing antibodies. Together with neutralization data, this data 
may mean that neutralizing antibodies play a role in protection against DF, but enhancing 
antibodies do not play a role in inducing DF. This would go along with the field’s idea about 
ADE; enhancing antibodies are not thought to induce mild DF but severe DHF. Even in the first 
study that correlated DHF with secondary infection, there was no difference between the 
occurrences of DF in primary or secondary cases [69]. Our study was not designed to explore 
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questions about the role of antibodies in DHF, which is typically seen in less than 5% of 
apparent dengue cases and 1% of dengue cases overall [228].  Even with rising incidence of 
severe dengue in Sri Lanka [39], our cohort size of 799 children was too small to obtain the 
number of DHF cases required for such analysis [8].   
The role of antibodies in inapparent infections is a neglected topic and increasingly 
relevant as dengue vaccines enter clinical trials.  Recent trial results of a highly-anticipated 
DENV vaccine candidate signify the importance of understanding the role pre-existing DENV 
neutralizing antibodies play in protection from subsequent dengue disease and clinical outcome 
[197]. Our findings point to an important role for heterotypic neutralizing antibodies in protection 
from dengue disease.  Further studies are needed to better define the protective properties of 
these cross-neutralizing antibodies.  
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Table 4.1.  Quantitative analysis of breadth of neutralizing antibody responses25 
 
Primary Infections 
Repeat Infections 
 
 
Inapparent Apparent  P value  
 
Median 25th 75th Median 25th 75th Median 25th 75th 
 
Baseline 
   
3.21 2.20 4.01 5.10 3.53 5.66 0.0326 
Follow-up 3.9127 2.52 4.51 3.17 1.74 4.91 1.49 0.90 2.82 0.0426  
Maximum Titer28 
Baseline 
   
4.39 3.55 5.40 4.58 3.78 5.10 0.5726 
Follow-up 4.39 3.73 6.69 6.48 5.61 7.26 5.87 5.03 6.67 0.0229 
 
                                                          
25Breadth of response expressed as log2(reciprocal neut50 titer/10), is a measure of the average difference in titer between the DENV 
serotype best neutralized by a serum (the maximum titer) and the titers for each of the other three DENV serotypes.  A value close to 
0 indicates the serum neutralizes all DENV types similarly, while higher values indicate that the serum neutralizes one DENV type 
significantly better than the other three types.   
 
26Wilcoxon rank sum test for difference between secondary inapparent and apparent infections. 
27Wilcoxon rank sum test for difference in breadth between primary infections and baseline secondary inapparent infection was not 
significant (p≅0.3). 
 
28Maximum titer for each individual, regardless of the infecting type, is shown. 
 
29Kruskal-Wallis test for difference in maximum titer between primary infections, inapparent and apparent repeat infections. 
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Figure 4.1. Pre-existing neutralizing antibody responses of repeat inapparent and 
apparent dengue infections. Baseline sera (when available) from repeat DENV infections 
were subjected to (A) IgG ELISA, (B-D) neutralization tests, and (D) IgM capture ELISA. (A) 
Baseline sera were used at 1:100 dilution. Mean OD405nm values for each group were calculated 
(represented by lines). Differences in mean OD between inapparent and apparent cases were 
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found to be insignificant by unpaired student’s t-test. (B-D) Baseline sera were subjected to 
neutralization assays at 1:40 – 1:10240 in 4-fold increments against DENV1-4. Sigmoidal 
curves were generated, and neut50 titers were calculated for each serotype. (B) Total neut50 is a 
calculation of each serum’s combined neut50 titer across all serotypes. Lines represent mean 
total neut50 values for each group and were found to be insignificant by unpaired student’s t-test. 
(C-D) Neutralization/Seroconversion threshold was set to ≥ 50% neutralization at ≥ 1:40 serum 
dilution for each DENV serotype. (D) Baseline sera were also subjected to IgM ELISA at 1:50 
dilution; IgM positivity was determined to be 5 standard deviations over NHS (N=10, pooled). 
(C-D) Groups were compared using Fisher’s exact tests, defining outcome categories as 
“monotypic” (seroconversion to one serotype) and “heterotypic” (seroconversion to ≥ 2 
serotypes). 
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Figure 4.2. Pre-existing enhancing antibody responses of repeat inapparent and apparent 
dengue infections. Baseline sera (when available) from repeat DENV infections were 
subjected to enhancement and neutralization tests. (A) Baseline sera were used in 
enhancement assay at 1:40 dilution. Percentage of infection was represented at number of 
standard deviations (SD) above mean % infection of NHS (N=10). Box and whiskey plots were 
generated for each group. Inapparent and apparent groups were compared for each DENV 
 73 
 
serotype and found to be insignificant by Mann Whitney test. (B) Baseline sera were subjected 
to neutralization assays at 1:40 – 1:10240 in 4-fold increments against DENV1-4. Sigmoidal 
curves were generated, and neut50 titers were calculated for each serotype. 
Neutralization/Seroconversion threshold was set to ≥ 50% neutralization at ≥ 1:40 serum dilution 
for each DENV serotype. Enhancement threshold was set to ≥ 10 SD above mean % infection 
of NHS (N=10). (C-F) Neut50 of each serum against (C) DENV1, (D) DENV2, (E) DENV3, and 
(4) DENV4 was compared to enhancement ability against the same serotype. (B-F) 
Neutralization and enhancement were compared by Pearson’s product moment correlation test. 
If no p-value is assigned, statistically analysis revealed an insignificant outcome. 
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CHAPTER FIVE 
Conclusions, Discussion, and Future Directions 
 
5.1 Overview of Research Purpose 
Research Significance 
  Dengue virus is estimated to infect about 390 million people per year, representing the 
greatest epidemiologic and economic burden of all mosquito-borne viruses in the world [24, 28]. 
Dengue disease manifests with a range of clinical symptoms that WHO traditionally groups into 
inapparent and apparent infections. Inapparent infections are subclinical asymptomatic 
infections; apparent infections present as DF, DHF, and DSS [35]. There are implications that 
both viral and host factors play a role in facilitating severe dengue disease outcome [31, 38, 42, 
43]. Antibody dependent enhancement is an immunopathological phenomenon thought to 
contribute most to dengue disease severity. This theory was formed in the 1980s [69] and has 
since been intensely studied [74, 78, 79, 88, 90-92, 94, 96, 105, 153, 226]. ADE is essentially a 
mechanism by which weakly-neutralizing cross-reactive antibodies bind to heterotypic DENV 
particles upon secondary infection, facilitating the uptake of those DENV particles into FcγR-
bearing monotypic cells. Through various mechanisms, viral burden is increased and severe 
DHF ensues. As with many of the other immune responses to DENV, human antibody 
responses are considered a double-edged sword of sorts. On one side, there are enhancing 
responses that increase pathogenesis, and on the other side there are neutralizing responses 
that induce protection. There is a breadth of research detailing both sides of the antibody 
double-edged sword, but there is still plenty that we do not understand [74, 77, 78, 88, 90-92, 
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94, 96, 101-103, 105, 153, 226]. Our lack of understanding about DENV antibody responses 
was solidified when a prospective DENV vaccine candidate revealed an unpredicted lack of 
protection following natural challenge [162, 179-182, 184, 186].  
Research Approach 
  A recent review eloquently pronounces 6 reasons why vaccine researchers could benefit 
from lessons taught by human cohort studies [138]. To date, prospective human cohorts from 
around the world have provided us with a glimpse of understanding about antibody responses 
[64, 70, 118, 121, 131, 138, 140, 142, 143, 148, 152, 154, 155, 160, 168, 182, 197, 229], 
proving that studying natural DENV infections in human cohorts is a beneficial method of 
answering some of the field’s most daunting questions. Our approach piggybacks on the 
relevance that human cohorts have to the dengue field. In collaboration with PDVI and 
investigators from the Ministry of Health in Sri Lanka, our group completed a prospective 
dengue study of 799 children, ages 0-12 years, who reside in Colombo, Sri Lanka. Using 
samples collected from the cohort, we addressed the field’s three overarching questions about 
human antibody responses to DENV infection:  
(1) What are the differences between antibody responses induced by primary versus 
secondary infections? 
(2) What role do enhancing antibodies play in disease severity? 
(3) What role do neutralizing antibodies play in protection from dengue disease?  
  In this chapter, I will discuss how our findings fit into the context of those three 
questions, suggest future directions for the Sri Lankan cohort, and close with an overview of the 
relevance of this work to the field and vaccine development in particular. 
5.2 Introduction to the Sri Lankan Pediatric Cohort 
Sri Lankan Pediatric Cohort Ideal for Studying Dengue Virus Antibodies 
 Before delving into the specifics of antibody responses in the Sri Lankan cohort, we first 
had to characterize DENV cases. Over the course of a year, between 2008 through 2009, 799 
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children were followed for fever occurrence. Children were bled at enrollment (baseline), and 
one year later (follow-up). If fever occurred, they were bled at the onset of fever (acute) and ≥ 
10 days following fever dissipation (convalescent) [215, 216]. The level of sero-prevalence at 
baseline in our cohort was 53.1%, meaning half of the children entered the cohort having 
already been exposed to DENV (Table 2.3). For those children who had been exposed to only 
one DENV serotype, as shown by a monotypic neutralization response at baseline, we 
determined that all DENV serotypes had previously been introduced to this population (Table 
2.4). Also, during the study year, children who got repeat infections were exposed to DENV1-4. 
The high level of initial sero-prevalence to all DENV serotypes and the circulation of all four 
DENV serotypes during the study year made this population ideal for studying pre-existing 
antibody responses. There is previous data linking specific serotypes to severe DENV 
epidemics and correlating sequence of infections to more severe 2° infections [32, 36-40]. A 
pitfall with our study is that clear conclusions based on serotype specificity of antibody 
responses could not be made; however, this means that our findings may be generalizable 
across antibody responses to multiple DENV serotypes. 
Comparison of Inapparent to Apparent Infection Ratios Across Cohorts 
In all, we characterized four classes of DENV infections: (1) 1° inapparent (N=20), (2) 1° 
apparent (N=15), (3) repeat inapparent (N=20), and (4) repeat apparent (N=12). The inapparent 
to apparent ratio was 1.48:1 (Table 2.5) [216]. There was no difference between the number of 
primary apparent and repeat apparent cases. Depending on cohort location and severity of the 
DENV season being monitored, cohorts from around the world have shown inapparent to 
apparent ratios ranging from 0.9:1 [200] through 13:1 [138, 139] (Table 1.2) [139]. Based on 
what we know about the prevalence of inapparent infections [28], the global ratio would be 
inferred to be about 3:1. Our ratio represents a few inherent factors of our cohort. Our apparent 
cases do not include DHF or DSS due to the small number of enrollees. 2008-2009 may have 
been a year for increased amount of DF cases in Sri Lanka, bringing the ratio closer to 1:1. 
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Evidence from Sri Lanka [39], and all over the world [230-238], shows that severe epidemics 
occur in temporal and spatial waves so we can assume that this ratio will change on an 
epidemic by epidemic basis.  Unlike many other cohorts, particularly those recording more 
apparent cases than inapparent cases, our surveillance methods were not hospital- or school 
absentee-based. Something is to be said about a possible skewing towards apparent cases if 
methods include enrolling individuals who present symptoms at a hospital or children who are 
absent from school due to illness.  
Importance of Using Neutralization Assays to Characterize Dengue Cases 
For those cohorts that have large inapparent to apparent ratios, false characterization of 
inapparent cases may have occurred due to assay sensitivity and specificity. We are confident 
that the burden of DENV we detected in our cohort is true because we utilized a gold-standard 
neutralization assay to detect repeat inapparent cases. Our FACS-based neutralization assay is 
a high-throughput 96-well plate method that allowed us to screen baseline and follow-up 
samples from all children for increases in neutralization capacity (Table 2.1). Use of such an 
assay is however tedious; therefore many cohorts also utilize haemagglutination inhibition (HAI) 
assays to detect secondary inapparent infections [139, 200]. IgG capture ELISA and HAI assay 
have been shown to detect 1° and 2° DENV infection comparably [239].  We tested the 
reliability of IgG ELISA to detect repeat inapparent DENV infections in our cohort. Using 
samples collected one year apart, we found that sensitivity and specificity of detecting repeat 
infections by IgG were 62.5% and 88.5%, respectively. These statistics were higher for primary 
infections, due to the positive predictability of IgG ELISA to simply detect seroconversion rather 
than antibody boosts. Using a virus-like particle neutralization assay [240] with samples from the 
Nicaraguan dengue cohort[139], researchers show similar sensitivity and specificity for HAI to 
detect 2° infections [Harris, Eva. | personal discussion at Dengue Vaccine Consultation Meeting 
2013]. That said, the number of inapparent infections in many cohorts may be overestimated. 
Some other cohorts present an advantage having collected samples in closer time intervals, 
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from which basic HAI or IgG assays may be able to detect increases in DENV-specific antibody 
capacity. But, our data suggest that it is worthwhile to always characterize DENV cases using 
gold-standard neutralization assays. True estimates of the global burden of DENV, stemming 
from properly characterized cohorts, will be important when determining vaccine implementation 
strategies. 
What Understanding True Burden of Dengue Infection in Sri Lanka Means to the Field 
 The Asian tropics represent a large portion (67%) of the global DENV infection burden. 
37% of that burden is said to come from the Indian subcontinent alone [28]. Sri Lanka, a country 
in the Indian subcontinent, has a high prevalence of DENV infection as evidenced by our 
aforementioned sero-prevalence data. Two million DENV infections are said to have occurred in 
Sri Lanka in 2010, based on surveillance cases reported to the WHO and cartographic 
estimates of global burden [28]. How accurate is that published estimate of 2 million infections in 
Sri Lanka per year? How accurate is the estimate of DENV burden for the entire Indian 
subcontinent? These are questions that only intense surveillance and detection of inapparent 
cases in a cohort, like the PDVI cohort, can answer. Data on Sri Lankan DF cases shows that 
even in highest incidence, 15,000 DF cases occurred annually through 2009 [204, 241]. Our 
characterization of inapparent infections allowed for us to estimate the true burden of DENV 
infections on the Indian subcontinent, for the first time. It will be interesting to see how our data 
influences future estimates of the burden of DENV in Sri Lanka.  
5.3 What are the differences between antibody responses induced by primary 
versus secondary infections? 
 
Current Understanding of Temporal Regulation of Dengue Virus Antibody Responses 
 
Having fully characterized primary and repeat DENV infections in the cohort, we set out 
to answer the question: What are the differences between antibody responses induced by 
primary versus secondary infections?. Primary and secondary infections are known to induce 
different antibody responses (Figure 1.5). Primary infections induce IgM responses that last up 
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to 6 months [112] and IgG responses that are lifelong [120]. We did not analyze IgG responses 
over time following 1° infections. Recently, when a group looked at IgG avidity over time, they 
showed IgG avidity waned after primary infections in positive correlation with decreasing 
neutralization breadth [113].   We found that following repeat infections, IgG responses 
fluctuated to some extent. From what we currently understand, secondary infections induce IgM 
responses that are shorter-lived and less robust than primary infections. After a secondary 
infection, IgG is boosted to a high level that is thought to last indefinitely [113, 114]. Our data 
shows that the IgG boost that is thought to occur after a secondary infection does in fact occur, 
particularly through convalescence (Figure 3.3). But following the convalescent stage, IgG 
antibodies return to baseline levels. This means that increases in DENV IgG after repeat 
infection are is not lifelong, as previously predicted. This may explain why IgG ELISA cannot be 
used to detect repeat inapparent infections. After a primary infection, IgG levels are increased; 
this is the level that we see at baseline. After 12 months, even if a dengue infection occurs, the 
boosted IgG responses have waned back to baseline levels. Therefore looking for significant 
increases in baseline and follow-up samples do not reveal an repeat inapparent infection.   
Predictions about Waning of Cross-protection 
Following 1° infections, the period of cross-protection is predicted to be anywhere from 3 
months, as shown in Sabin’s human challenge studies [119], up to 2 years, as shown in 
naturally-infected people [118, 121]. In our cohort, cross-neutralization is defined as having 
sero-positivity to ≥ 2 DENV serotypes. Using linear regression analysis, we show neutralization 
breadth wanes with time elapsed after 1° DENV infection (Figure 3.2A). At 10 months post-
primary infection, there were still two children who exhibited cross-neutralization, one of which 
neutralized all serotypes. In the period of 10-12 months, neutralization breadth becomes specific 
to one DENV serotype. Perhaps, the cross-neutralization capacity of the remaining broad-
neutralizers lasts up to 2 years like shown in previous cohorts [118, 121], but we will have to 
follow the children for longer to determine this to be true.  
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Interestingly, the period of cross-protection, in our study and others, lasts beyond the 
known period of IgM presence. That said, other studies have correlated IgM with cross-
protection [113]; we did as well (Figure 3.2B). IgM positivity even correlated with neutralization 
titers (Figure 3.2D). This has been shown previously, as well [113]. Together, this data would 
suggest a role for IgM antibodies in early cross-neutralization, but there must be other types of 
antibodies, besides IgM, responsible for cross-protection beyond the 6 month mark. Following 
post-secondary infections, lifelong cross-protection is insinuated [116].  
What we saw with neutralization responses following repeat infections was markedly 
different than what we saw with repeat IgG responses. Also, neutralization capacity following re-
infections did not wane, as it did following 1° infections, but remained steady through the end of 
the study year (Figure 3.3B-C). This goes along with what we believe about protective antibody 
responses following secondary infections [116]. 
Neutralization Magnitude versus Neutralization Breadth 
Characterizing neutralization breadth is a standard way by which neutralization capacity 
is determined [116]. But, there is another important aspect of neutralization capacity… 
magnitude. There are disagreeing data on whether pre-existing neutralization titers correlate 
with protection from subsequent DENV infection [152, 155] [Buddhar, Darunee, et al. | 
unpublished data submitted to PLoS Neglected Tropical Diseases]. Therefore, we felt that it was 
worthwhile to look at neutralization magnitude in our cohort. Before discussing our findings, it 
must be noted that there are pitfalls of drawing conclusions from neutralization titers. To date, 
no specific neutralization titer has been pinpointed as a correlate for protection. Because there 
are four DENV serotypes, it is quite possible that such a correlate would be different based on 
serotype, and even genotype. Recent failure of a dengue vaccine to protect against a particular 
DENV2 genotype draws eminent concern to that point [162, 180]. Also, researchers have their 
own favorite methods for detecting DENV neutralization [155, 214, 240, 242]. Variability across 
assays, and even within assays on a day-to-day basis, creates concerns about conclusions 
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drawn without use of an acceptable number of experimental replicates. All of these things could 
be reasons why previous data is conflicting.  
To satisfy some of those concerns, our FACS-based DENV neutralization assay has 
been compared to a standard plaque-based neutralization assay [213]. Additionally, in this 
study, we tested the assay for reproducibility in detecting DENV infections (data not shown), 
and each confirmed DENV case was tested at least twice to determine neut50 titers. We first 
showed that following 1° infections, while there was a trend towards negative correlation 
between neutralization breadth and time elapsed, neutralization titers did not decrease 
significantly over time like neutralization breadth (Figure 3.2C). It is worthwhile to note that the 
most significant of these correlations was that between neutralization titers of serotypes of non-
exposure and time elapsed. Essentially, that means that magnitude of cross-neutralizing 
responses wanes quicker than magnitude of type-specific responses.  
In the acute phase following repeat infections, we noticed neutralization magnitude 
increased to only one serotype, likely the serotype of previous infection. There was an 
abundance of strong broadly-neutralizing antibodies at the convalescent stage (Figure 3.3) 
(some data not shown | Corbett, Kizzmekia, et. al | manuscript in press in Journal of Infectious 
Diseases).  Another study showed the same type of robustly increasing neutralization through 
the convalescent stage of infection [113].  At follow-up, we could not determine the relative 
contribution of neutralization capacity as it related to infection history so we cannot definitively 
state that the previously infecting serotype is responsible for the highest boosted response. But 
overall, the temporal trends of neutralization magnitude seen after repeat infections may be 
associated with original antigenic sin, which has been described for DENV infections [243-247]. 
5.4 What role do enhancing antibodies play in disease severity? 
Using K562 Cells to Determine DENV Enhancement 
 We then asked: What role do enhancing antibodies play in disease severity? This 
question is of particular interest with the plethora of data showing DENV enhancing antibodies 
 82 
 
can facilitate the uptake of DENV particles into cells to cause an increased viral burden and 
severe disease [74, 78, 79, 88, 90-92, 94, 96, 105, 153, 226]. We subjected baseline samples 
from children who acquired repeat DENV infections to a K562 cell-based enhancement assay 
[226]. This is a pitfall of our study because these cells only contain FcγRIIa, which is considered 
the stimulatory FcγRII isotype [86, 226]. Without the presence of its inhibitory counterpart, 
FcγRIIb, FcγRIIa could provide a biologically-irrelevant idea of true DENV enhancement. U937 
cells, which contain FcγRIIa and FcγRIIb, were tested but did not induce significant enough 
enhancement, perhaps due to technical issues. Primary human monocytes, which we also 
tested (data not shown), are the most relevant cell type to test DENV enhancement, but lack of 
availability of large batches of these cells called for a more feasible alternative in order to test all 
of our samples repetitively.  
Dengue Antibody Dependent Enhancement and Mild Disease 
We didn’t find a difference in the ability of pre-existing antibodies from repeat inapparent 
and apparent infections to enhance DENVs (Figure 4.2). Without any severe DHF or DSS 
cases, we cannot draw any strict conclusions about the role of enhancing antibodies on dengue 
disease severity as a whole. What we can say is that enhancing antibodies did not play a role in 
inducing DF in our cohort. We were not surprised by this result because enhancing antibodies 
are not thought to differentiate between inapparent and mild DF [69]. Despite this finding, we 
were able to negatively correlate enhancement to neutralization; the balance between 
pathogenic and protective antibody responses which will be discussed later in the chapter. 
5.5 What role do neutralizing antibodies play in protection from dengue disease? 
Protection from Apparent Dengue Infection Facilitated by Cross-Neutralizing Antibodies 
 From a vaccine development perspective, it is of particular importance that we 
understand the role neutralizing antibodies play in protection from dengue disease. In that 
aspect, the fact that there were no DHF or DSS cases in our cohort presented an opportunity to 
examine fine-tuned protection between inapparent and mild DF cases. Starting with simple pre-
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existing DENV-binding IgG antibody responses, we did not see a difference between repeat 
inapparent and apparent cases (Figure 4.1A). Our IgG ELISA uses a 1:1:1:1 mixture of 
DENV1-4 as antigen [31, 39]. There is an abundance of cross-reactive antibodies after DENV 
infections. Recent studies have shown that most of these cross-reactive antibodies are weakly-
neutralizing and even sometimes enhancing [76, 105]. By accessing DENV binding to our 
antigen mixture, OD readout was just a gauge of DENV cross-reactivity, not a gauge of actual 
antibody function.  
As shown in chapter 3, cross-reactive IgG after 1° infections may exist, but neutralization 
capacity wanes. That known, we tested baseline sera from children who got repeat infections for 
DENV-specific neutralization. We didn’t find a difference in neutralization magnitude (Figure 
4.1B). This finding goes along with previous findings that absolute DENV neutralization titers 
cannot be used a correlate of protection [152, 155]. We did however find that neutralization 
breadth correlated with clinical outcome of dengue infection. Children who got repeat inapparent 
infections had more broadly-neutralizing pre-existing DENV antibodies than children who got 
apparent re-infections (Figure 4.1C).  
Quantitative Analysis of Breadth of Neutralizing Antibody Responses 
We quantified neutralization breadth by inserting our neutralization data into a 
cartography algorithm for determining distance between the best-neutralized DENV serotype 
and other serotypes; similar methods have been used for influenza studies [248]. To better 
imagine the concept, think of the 4 DENV serotypes being placed on a map based on their 
antigenic distances from each other. With the algorithm, each serum tested was placed within 
that map based on serotype-specificity of neutralization titers. Type-specific sera clustered 
around one serotype and broadly-neutralizing sera clustered in the middle of multiple serotypes. 
The placement of groups of sera on said hypothetical map is represented by the numbers 
shown in table 4.1. A value closer to 0 essentially means the sera reside in the middle of the 
map and neutralize all DENVs similarly.  
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There are pitfalls to our method though; most notable is that we assumed the DENV 
serotype that a person neutralized best was the previously infecting serotype. That assumption 
may not hold true knowing what we know about the differential ability of DENV serotypes to be 
neutralized in the neutralization assay [214]. For those sera that neutralize more than one 
serotype, it is difficult to tell which serotype is responsible for the infection. To eliminate much of 
our concern about this, we compared PCR data from acute infections with neutralization titers at 
follow-up, following 1° apparent infections; we found our predictions of infecting serotypes 
based on neutralization titers held true most of the time (data not shown). Another pitfall is the 
use of a neut50 titer of 20 in instances when a serum did not neutralize a serotype. Although the 
lowest dilution we used in our assays was 1:40, we chose 1:20 based on it being the lowest 
dilution typically used in neutralization assays [213, 214], but there is no biological basis to 
justify this cutoff.  Use of ≤1:40 dilutions was not feasible due to limited DBS availability. Pitfalls 
aside, our quantitative analysis further exemplified what we saw when we looked at 
neutralization breadth: children who got repeat inapparent infections had pre-existing DENV 
antibodies that were more active against all DENV serotypes than children who got apparent re-
infections (Table 4.1). With that, we propose that this algorithm be used as a secondary method 
to determine neutralization breadth in studies of this nature. 
Explanations for Correlation between Breadth of Neutralization and Dengue  
Disease Outcome 
 
Our findings demonstrate an association between breadth of pre-existing DENV 
neutralizing antibodies and the likelihood of developing an inapparent versus apparent infection.  
For only the second time in the field has a role for pre-existing neutralizing antibodies in 
protection against apparent dengue infections been shown. In the first study, individuals were 
extensively followed in Peru; 1°, 2°, and post-secondary infections were characterized [116]. 
This study showed that breadth of pre-existing neutralization antibodies correlated with 
protection from post-secondary infections, but not 2° infections. This brings me to a particularly 
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relevant point when thinking about what our data mean about protection. Because we have yet 
to decipher the children’s infection histories, it is impossible for us to differentiate between 2° 
and post-secondary infections. We tried to determine prior infection history based on 
neutralization profiles of baseline samples, but this method did not produce clear results (data 
not shown). The only indication we have that these infections are “true” secondary infections is 
that the degree of neutralization breadth observed at baseline for repeat cases was not 
significantly different from the degree of neutralization breadth at follow-up for 1° cases (Table 
4.1).  
The other non-exclusive possibility for our finding is that individuals who have cross-
neutralizing antibodies at baseline got their previous infection recently, within the window of time 
that cross-neutralization exists. Experimentally, we could not determine if previous infections 
occurred in the entire 1-2 year window of cross-protection, but we utilized IgM as a marker for 
determining recent previous infections, within the last 6 months. There was no correlation 
between neutralization breadth and IgM response in baseline samples from these children 
(Figure 4.1D). This data suggests that recent infection within the last 6 months cannot be used 
to explain the association between broad-neutralization and protection. The simplest 
explanation for this association is that some individuals inherently induce long-lived broadly 
neutralizing responses after primary infections. Our data showing broad-neutralizing antibody 
responses up to 10 months after some primary infections would suggest that this as a 
possibility. All possibilities considered, it is most logical that a combination of time since 
previous exposure and infection history influence one’s ability to neutralize multiple serotypes, 
consequently influencing protection from apparent dengue disease. 
Balance Between Pathogenic and Protective Antibody Responses 
 Progression towards or protection from DENV diseases is likely a matter of the balance 
between enhancing and neutralizing antibody responses [115]. Comparisons between 
neutralizing and enhancing antibodies have been made in mouse models and other human 
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cohorts [137, 249, 250]. We tested the theory of pathogenic versus protective responses using 
samples from our cohort. For DENV1-3, as a child’s neutralization capacity increased, their 
ability to enhance that serotype decreased (Figure 4.2C-E). We did not see this trend with 
DENV4 (Figure 4.2F) which may be due to the fact that the ability of these sera to neutralize 
DENV4 was typically low. The negative correlation we see with neutralization and enhancement 
in this cohort justifies the idea that neutralizing and enhancing antibodies are completely 
different antibodies. An analysis of the correlation between neutralization titer against 
heterotypic serotypes and enhancing ability would have been nice to further solidify this idea. In 
just, we found a correlation between neutralization breadth and protective disease outcome, but 
did not find a correlation with enhancement ability and clinical disease outcome. Therefore, with 
regards to differentiating between inapparent and mildly apparent dengue cases, pre-existing 
neutralization capacity is more telling.  
5.6 Snapshot of Research Findings 
In summary, we drew the following major conclusions from our studies: 
(1) What are the differences between antibody responses induced by primary versus 
secondary infections? 
a. IgG ELISA was determined to be unreliable for detecting repeat DENV infections 
utilizing paired samples collected 12 months apart. 
b. Primary inapparent and apparent DENV infections result in similar IgG and 
neutralization capacity. 
c. After 1° infections, neutralization capacity is negatively correlated with time 
elapsed since DENV exposure. 
d. Following repeat DENV infections, IgG levels increase during a brief span around 
febrile illness, but eventually decline to baseline levels. On the other hand, 
neutralizing antibody capacity increases and remains steady.  
(2) What role do enhancing antibodies play in disease severity? 
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a. There was no correlation between pre-existing enhancement capacity and 
inapparent or apparent outcome following repeat infection. 
b. Pre-existing neutralization capacity and enhancement ability were negatively 
correlated. 
(3) What role do neutralizing antibodies play in protection from dengue disease?  
a. Repeat inapparent infections are more likely to occur in children with broadly-
neutralizing pre-existing antibody responses than repeat apparent infections, 
indicating an association between neutralization breath and protection from 
apparent DENV infection.  
b. Breadth of pre-existing neutralizing antibodies is not correlated with IgM level, 
and thus not indicative of previous DENV exposure within the last 6 months. 
 Able oFuture Directions  
Dissecting Infection History of Children with Repeat DENV Infections 
Our findings leave a wide-open arena for exploration of specific mechanisms of pre-
existing neutralizing antibody responses to DENV infections as they correlate with protection. It 
will be important to dissect infection history of children with repeat DENV infections to determine 
whether children exhibiting broadly-neutralizing baseline antibodies have been previously 
exposed to dengue more than once. This will also allow us to test the hypothesis that serotype 
specificity of prior DENV exposure influences neutralization/protection or lack thereof (perhaps 
enhancement) upon repeat exposure. As aforementioned, neutralization responses at baseline 
do allow us to decisively determine infection history.  
Therefore, we propose a couple of options for dissecting infection history using samples 
from our cohort. One method is to deplete baseline sera with native dengue virions of particular 
serotypes and then assess neutralization capacity of depleted sera [77]. If a serum contains 
type-specific neutralizing responses to ≥ 2 serotypes following depletion, that individual has 
been exposed to DENV multiple times prior to enrollment. The other method is to use a 
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blockade of binding (BoB) assay. In BoB assays, DENVs are captured on 96-well plates, 
experimental sera are allowed to bind to DENVs, then a flourochrome-conjugated type-specific 
mAb is added. If antibodies in a serum block binding by the mAb that means that there are type-
specific antibodies in said serum. If a serum contains type-specific responses to ≥ 2 serotypes 
in the BoB assay, that individual has been exposed to DENV multiple times prior to enrollment. 
Dissecting Epitope-Specificity of Pre-existing Antibodies  
One could take this analysis a step further to dissect epitope-specificity of pre-existing 
antibodies in children with repeat DENV infections, testing the hypothesis that quantity of pre-
infection antibodies that target prM and E fusion loop epitopes (highly-conserved regions) 
correlate with cross-neutralization [104, 106, 222]. Conversely, we can test the hypothesis that 
quantity of pre-infection antibodies that target the EDI/II region correlates with type-specificity 
[76, 77, 102, 103]. A strategy by which to pursue this direction was previously published [106]. 
Briefly, anti-FL antibodies were determined by capture ELISA using FL-mutated VLPs. The 
concentration of anti-FL antibodies in each serum was correlated with neutralization capacity. A 
similar approach can be used for all relative epitopes of DENV. Also we could generate huMAbs 
from PMBCs collected from these children, as previously described [74]. We could then use 
neutralizing huMAbs to apply pressure to DENVs in culture to generate escape mutants, which 
will allow us to map epitope-specificity the huMAbs [76]. 
Following Cohort into Year Two of Sample Collection and Possibly into a Vaccine Trial  
Additionally, a second year of samples was collected from 2009 through 2010, which we 
did not completely analyze for the purposes of this dissertation. Based on our own preliminary 
analysis and knowledge that a wave of severe DENV1 replaced DENV2/3 in Colombo, Sri 
Lanka during that year [33], we suspect many interesting findings will come from applying the 
specific aims from this dissertation to those samples. The most interesting experiments would 
be a detailed analysis of burden of DENV infection in year 2, from which, we could compare 
inapparent to apparent infection ratios across two markedly different epidemics and provide the 
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field with a longer-termed analysis of the burden of DENV infection in Sri Lanka. We could also 
determine, once infection history is assessed, if there is a particular level of immunity to certain 
serotypes that render 2° DENV1 infections more or less severe. Cohorts like this provide the 
ideal setting for vaccine trials because the participants’ previous DENV immunity is mapped out 
in detail. Introducing a dengue vaccine candidate into this cohort could provide the field with an 
understanding of how pre-existing immunity affects vaccine efficacy.  
5.8 Closing Statement 
This dissertation details the characterization of human antibody responses to DENV 
infections in a Sri Lankan Pediatric Cohort. We were able to characterize the true burden of 
DENV infection in the Indian subcontinent, analyze the temporal regulation of antibodies 
following DENV infections, and, most importantly, correlate DENV neutralization breadth with 
protection from subsequent apparent DENV infection. This finding implicates neutralization 
capacity as having an important role in protection against clinical manifestations. Our research 
is innovative because it is based on existing clinical samples collected from a cohort of children 
before and after experiencing inapparent and apparent DENV infections. DENV vaccine 
development is hindered by a gap in understanding of the properties of antibodies that protect 
or possibly enhance disease. Our results will provide insight into pre-existing antibody 
responses that correlate with protection. These findings may be applicable to developing and 
evaluating DENV vaccines in the future.  
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